Page last updated: 2024-10-29

ifosfamide and Soft Tissue Neoplasms

ifosfamide has been researched along with Soft Tissue Neoplasms in 286 studies

Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.

Research Excerpts

ExcerptRelevanceReference
"The results of the association of doxorubicin plus ifosfamide in the treatment of locally advanced and/or metastatic adult soft tissue sarcomas as reported in the literature from 1986 up to the present time are reviewed."10.17Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. ( Palumbo, R; Santi, L; Sogno, G; Toma, S; Venturino, A, 1992)
"This randomised phase II/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior to the standard Adriamycin plus ifosfamide (AI) in terms of overall survival (OS) in patients with soft tissue sarcoma (STS)."9.51Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306. ( Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T, 2022)
"This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS)."9.51Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. ( Chen, H; Chen, Y; Huang, M; Jiang, S; Liu, X; Luo, Z; Miao, J; Wang, C; Wang, H; Wang, J; Wu, X; Xia, J; Xu, Y; Yan, W; Yao, W; Yu, L; Zhang, X, 2022)
"Doxorubicin and ifosfamide (AI) is standard therapy for high-risk soft tissue sarcoma (STS) but often causes severe toxicities resulting in hospitalisation."9.20A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L, 2015)
"Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role."9.19Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. ( Alcindor, T; Blay, JY; dei Tos, AP; Fisher, C; Gelderblom, H; Hartmann, JT; Hermans, C; Hogendoorn, PC; Hohenberger, P; Judson, I; Kerst, JM; Krarup-Hansen, A; Litière, S; Marreaud, S; Schöffski, P; Sufliarsky, J; van der Graaf, WT; Verweij, J; Whelan, J, 2014)
" Perioperative chemotherapy with adriamycin plus ifosfamide is the current standard treatment for T2bN0M0 high-grade non-round cell soft tissue sarcoma."9.19A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306. ( Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K, 2014)
"The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy."9.17Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013)
"This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens."9.17Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013)
"Ifosfamide and doxorubicin combination is an active regimen for patients with advanced soft tissue sarcomas (STS) but is burdened by high toxicity."9.15Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. ( Boni, C; Boselli, S; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Frustaci, S; Noberasco, C; Radice, D; Rosati, G; Scalamogna, R; Spitaleri, G; Toffalorio, F; Tucci, A; Vecchio, F, 2011)
"To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma."9.14Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. ( Andrés, R; Balañá, C; Buesa, JM; Casado, A; Cruz, J; Cubedo, R; de la Cruz, JJ; de Las Peñas, R; Del Muro, XG; Fra, J; Gallego, O; Gómez, MA; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Rubió, J; Rubio-Viqueira, B; Sevilla, I, 2009)
"Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas."9.12Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. ( Cerny, T; Christinat, A; Dietrich, D; Fey, MF; Guillou, L; Herrmann, R; Honegger, HP; Leyvraz, S; Pestalozzi, B; Sessa, C; Wernli, M, 2006)
"Combinations of high-dose ifosfamide (IF; 10-12 g/m2) plus doxorubicin (DX; 50-90 mg/m2) have been administered to patients with advanced soft tissue sarcoma (ASTS) in an attempt to improve therapeutic efficacy."9.11Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). ( Balañá, C; Buesa, JM; Casado, A; de las Peñas, R; Fra, J; García del Muro, X; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J, 2004)
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear."9.11Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005)
"To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin."9.11Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. ( Devidas, M; Gebhardt, M; Grier, HE; Jenkins, J; Marcus, R; Pappo, AS; Pratt, C; Rao, B; Thomas, P, 2005)
"Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas."9.11Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas. ( Abe, S; Araki, N; Beppu, Y; Hasegawa, T; Ihara, K; Ishii, T; Isu, K; Kawai, A; Ozaki, T; Sugiura, H; Tsugane, S; Umeda, T; Wada, T; Yabe, H, 2005)
"The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy."9.10Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002)
"We conducted our study to determine the pharmacokinetics (PK) and clinical efficacy of oral mesna in patients receiving ifosfamide for soft tissue sarcoma."9.10Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. ( Baker, LH; Bernardy, H; Demetri, G; Junge, K; Keohan, ML; Mace, JR; Mueller, U; Niebch, G; Romeis, P; Thoma, A; Wagner, T, 2003)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."9.10Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
"The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR)."9.09Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Gwyther, SJ; Judson, IR; Nielsen, OS; van Glabbeke, M; Verweij, J, 2000)
"The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)."9.09A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001)
"The Epirubicin (EPI) and ifosfamide (IFO) combination has been widely tested in soft tissue sarcomas, even though the optimal schedule of drug administration has still to be defined."9.09Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules. ( Cognetti, F; Nardoni, C; Pacetti, U; Papaldo, P; Serrone, L; Zeuli, M, 2001)
"Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study."9.09Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001)
" ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma."9.09Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001)
"Ifosfamide, an oxazaphosphorine analogue, is now commonly used in first-line anthracycline-containing regimens for advanced soft tissue sarcomas, based on its demonstrated single-agent activity in previously treated patients."9.08High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. ( Tursz, T, 1996)
"To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas."9.08High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997)
"The purpose of this study was to evaluate tumour response and toxicity to ifosfamide and continuous infusion etoposide in metastatic or locally advanced soft tissue sarcoma, with dose escalations under G-CSF (granulocyte colony-stimulating factor) support."9.08Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. ( Alvegård, TA; Erlanson, M; Hannisdal, E; Klepp, R; Monge, OR; Raabe, N; Saeter, G; Söderberg, M; Solheim, OP; Strander, H; Turesson, I; Wist, E, 1997)
"Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent."9.08Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. ( Antimi, M; Gatti, C; Palmeri, S; Palumbo, R; Raffo, P; Toma, S; Villani, G, 1997)
"The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses < or = 10 g/m2 show remissions when exposed to high-dose ifosfamide (HDI) (i."9.08Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) ( Antón, A; Arranz, F; Bellmunt, J; Buesa, JM; Casado, A; Escudero, P; García del Muro, J; López-Pousa, A; Martín, J; Menéndez, D; Poveda, A; Valentí, V, 1998)
"Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship."9.08Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998)
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship."9.08High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998)
"The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma."9.07Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994)
"5 g/m2 mesna was administered for 7 days, both by continuous infusion, in combination with 50 mg/m2/d oral etoposide for 8 days in 21 patients with sarcomas or other solid tumors."9.07Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. ( Hamdan, H; Skubitz, KM; Thompson, RC, 1993)
"To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients."9.07Epirubicin and ifosfamide in advanced soft tissue sarcomas. ( Buonadonna, A; Carbone, A; Crivellari, D; De Paoli, A; Foladore, S; Frustaci, S; Monfardini, S; Morassut, S; Sorio, R, 1993)
"This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin."9.07Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. ( Blum, RH; Brooks, JS; Edmonson, JH; Frytak, S; Parkinson, DR; Ryan, LM; Shiraki, M, 1993)
"Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas."9.07An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft-tissue sarcoma."9.07Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Steward, W; Thomas, D; van Oosterom, AT; Verweij, J, 1993)
"A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna."9.07Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. ( Azzarelli, A; Casali, P; Fissi, S; Montalto, F; Quagliuolo, V; Santoro, A, 1993)
"The Southwest Oncology Group (SWOG) performed a phase II trial of a combination of ifosfamide/mesna/cisplatin in patients with metastatic soft-tissue sarcoma who had previously received one chemotherapeutic regimen."9.07Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. ( Balcerzak, SP; Budd, GT; Fabian, C; Metch, B; Stephens, RL; Weick, JK; Weiss, SA, 1993)
"On the basis of ifosfamide's demonstrated single-agent activity in adult soft-tissue sarcoma, the Eastern Cooperative Oncology Group (ECOG) tested whether ifosfamide would add to the efficacy of doxorubicin in a three-regimen, controlled phase III trial."9.07Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. ( Blum, RH; Edmonson, J; Pelletier, L; Ryan, L, 1993)
"A total of 37 adult patients with locally advanced or metastatic soft-tissue sarcoma (STS) entered a pilot study of combination chemotherapy based on the CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) regimen, in which cyclophosphamide was replaced by ifosfamide and mesna (1 g/m2 ifosfamide given daily on days 1-5 as 2-h infusions, 1."9.07Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. ( Blomqvist, CP; Elomaa, I; Virolainen, M; Wiklund, TA, 1992)
"Doxorubicin and ifosfamide are the two most active agents used in the treatment of advanced inoperable soft-tissue sarcoma, but their use in combination produces dose-limiting myelosuppression."9.07Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Blackledge, G; Clavel, M; Greifenberg, B; Soedirman, J; Somers, R; Steward, WP; Thomas, D; Van Glabbeke, M; Van Oosterom, AT; Verweij, J, 1991)
"European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas."9.06Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989)
"In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)."9.06Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989)
"One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i."9.06Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."8.91Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015)
"The authors report a retrospective analysis of high-dose ifosfamide, carboplatin, and etoposide (HD-ICE) for patients with refractory or relapsed neuroblastoma (NB)."8.89Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. ( Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS, 2013)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."8.88Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012)
"Independent favourable prognostic factors for overall survival (OS) were good performance status, female gender, low histological grade, extremity primary tumour site and locally advanced disease; for progression-free survival (PFS), the combination of doxorubicin and ifosfamide, locally advanced disease, and tumour entity with a lower risk to progress for synovial sarcoma patients compared to leiomyosarcoma."8.86Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr ( Blay, JY; Hogendoorn, PC; Krarup-Hansen, A; Le Cesne, A; Ouali, M; Rodenhuis, S; Sleijfer, S; van Glabbeke, M; Verweij, J, 2010)
"Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma."8.86Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."8.86Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010)
"The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas."8.81Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001)
"Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease."8.79High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996)
"We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985."8.78Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993)
"Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults."8.78Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. ( Azzarelli, A; Bertulli, R; Casali, P; Devizzi, L; Pastorino, U; Santoro, A; Zucchinelli, P, 1993)
"Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas."8.78The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990)
"The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas."8.77The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989)
"We conducted a multi-institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy."8.12Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. ( Agulnik, M; Davis, LE; Godbole, S; Hirbe, AC; Livingston, JA; Miller, D; Park, Y; Parkes, A; Posey, K; Robinson, SI; Skubitz, K; Van Tine, BA, 2022)
"To investigate the value of contrast-enhanced computed tomography (CECT) radiomics features in predicting the efficacy of epirubicin combined with ifosfamide in patients with pulmonary metastases from soft tissue sarcoma."8.12Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features. ( Jiang, X; Li, M; Ma, ST; Miao, L; Wang, YM; Zhang, HH, 2022)
"To compare long-term outcomes of high-grade, primary soft-tissue-sarcoma (STS), using Ifosfamide-Doxorubicin vs local therapy alone, in histology-specific sarcomas."8.02The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience. ( Burchette, RJ; Goy, BW; Helmstedter, CS; Padmanabhan, A; Syed, S, 2021)
"We compared the outcomes in soft tissue sarcoma (STS) treated with olaratumab and doxorubicin (OD) versus doxorubicin, ifosfamide, and mesna (AIM) to assess whether OD could supersede AIM in STS therapy."7.96Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. ( Copeland, VC; Cranmer, LD; Hammer, KJ; Loggers, ET; Pollack, SM; Wagner, MJ, 2020)
"A retrospective search of the Royal Marsden Sarcoma Unit Database was performed to identify patients initially treated with ifosfamide (as single agent or in combination) and who were subsequently rechallenged with single-agent ifosfamide."7.88Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. ( Benson, C; Constantinidou, A; Jones, RL; Judson, I; Messiou, C; Miah, A; Noujaim, J; Thway, K, 2018)
"We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS)."7.85VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. ( Baek, SW; Choi, YS; Jo, DY; Kim, S; Lee, HJ; Moon, JY; Ryu, H; Song, IC; Yun, HJ, 2017)
"The combination of topotecan and cyclophosphamide is active in relapsed Ewing sarcoma family of tumors (ESFT)."7.83Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. ( Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB, 2016)
"Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma."7.71[Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma]. ( Chen, LK; Liang, Y; Liu, JL; Teng, XY; Xu, GC; Zhou, XM, 2002)
"Ifosfamide is a leading drug in soft tissue sarcoma therapy."7.70Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998)
"From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)."7.69[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997)
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects."7.68[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993)
"Between 1982 and 1986, 38 patients with soft-tissue sarcomas were treated with the combination doxorubicin/dacarbazine (group A); between 1986 and 1990, another 46 patients received doxorubicin/ifosfamide (group B); and between 1990 and 1991, 11 patients received an alternating regimen of doxorubicin and ifosfamide (group C)."7.68Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. ( Agarwal, K; Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Zornig, C, 1993)
"Two trials using ifosfamide-based combination chemotherapy for advanced soft-tissue sarcoma have been completed."7.68Ifosfamide combination regimens for soft-tissue sarcoma. ( Bell, DR; Dalley, D; Levi, J; Simes, RJ; Stuart-Harris, R; Wiltshaw, E, 1993)
"The response of ifosfamide-based chemotherapeutic regimens was retrospectively analyzed in adult patients with advanced soft-tissue sarcoma who were treated at the West German Tumor Center, Essen, between 1978 and 1990."7.68Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. ( Kellner, R; Schütte, J; Seeber, S, 1993)
"Currently, anthracyclines and ifosfamide are the most effective drugs for the treatment of disseminated soft-tissue sarcoma."7.68A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. ( Anagnou, J; Bokemeyer, C; Harstrick, A; Knipp, H; Köhne-Wömpner, CH; Neumann, S; Poliwoda, H; Schmoll, HJ; Schöffski, P; Wipperman, B, 1993)
"A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)."7.68Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993)
"Twenty-eight patients with non-pretreated metastatic soft tissue sarcomas were entered on a treatment protocol of rapidly alternating epirubicin/dacarbazine and ifosfamide: Epirubicin 100 mg/m2 d1, dacarbazine 500 mg/m2 d1 + d2, ifosfamide 6000 mg/m2 24-h infusion d15; repeated d29."7.68Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ( Bokemeyer, C; Harstrick, A; Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöffski, P, 1992)
"From July 1986 to July 1989, 40 patients (92% pretreated) with deep-seated, advanced soft tissue sarcomas (STS, 25 patients), Ewing's sarcomas (ES, eight patients), osteosarcomas (OS, three patients) and chondrosarcomas (ChS, four patients) were treated at the University of Munich in a protocol involving regional hyperthermia (RHT) combined with ifosfamide plus etoposide."7.68Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. ( Berger, H; Boehm, E; Denecke, H; Issels, RD; Jauch, KW; Nagele, A; Peter, K; Prenninger, SW; Sauer, H; Wilmanns, W, 1990)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma."7.68Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990)
"Forty-three adult patients with locally advanced or metastatic soft tissue sarcoma entered a pilot study of combination chemotherapy comprising 50 mg of doxorubicin/m2 by intravenous bolus, 850 mg of dacarbazine/m2 by 1-hour infusion, and 5 g of ifosfamide/m2 by 24-hour infusion with mesna uroprotection."7.67Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. ( Bramwell, V; Eisenhauer, E; Knowling, M; Quirt, I; Verma, S; Warr, D; Young, V, 1989)
"Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients."7.67Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986)
"Fifty-four patients with advanced soft tissue sarcoma were treated with a combination of ifosfamide (5 g/m2) and adriamycin (40-60 mg/m2) at 3 weekly intervals."7.67A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. ( Fisher, C; King, M; MacMillan, S; Mansi, JL; Stuart-Harris, R; Wiltshaw, E, 1988)
"We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors."7.67A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986)
" Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment."7.67Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985)
"In a phase II study, 42 patients with advanced soft-tissue sarcoma were treated with ifosfamide by 24-h infusion and mesna by 4-h IV bolus, repeated every 3 weeks."7.66High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. ( Gowing, NF; Harper, PG; Kaye, SB; Mooney, CA; Parsons, CA; Stuart-Harris, RC; Wiltshaw, E, 1983)
"Patients <30 years old with Ewing sarcoma were eligible."6.80Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. ( Abujamra, AL; Almeida, MT; Benites, E; Boldrini, E; Brunetto, AL; Castillo, LA; Costa, C; Gadelha, A; Gregianin, LJ; Kirst, D; Macedo, CD; Morais, V; Nakasato, A; Pereira, WV; Petrilli, AS; Pizza, M; Rodriguez-Galindo, C; Watanabe, FM, 2015)
"Ifosfamide is a chemotherapeutic agent that requires cytochrome P450 3A (CYP3A) for bioactivation and metabolism."6.73Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. ( Baker, LH; Chugh, R; Griffith, KA; Leu, KM; Taylor, JM; Thomas, DG; Wagner, T; Worden, FP; Zalupski, MM, 2007)
"Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy."6.72Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. ( Abdel-Rahman, S; Baumert, J; Falk, M; Hentrich, M; Hiddemann, W; Issels, RD; Licht, T; Salat, C; Schlemmer, M; Straka, C; Wendtner, CM, 2006)
"Etoposide monotherapy was successful in 8%; the effectiveness of cisplatin was 5-23%."6.69The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. ( Bodoky, G; Eckhardt, S; Láng, I; Pápai, Z; Poller, I; Rahóty, P; Szántó, J; Szendroi, M, 2000)
"Gemcitabine was administered as a 360 min infusion on days 1, 8 and 15 of a 28 day cycle."6.69Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. ( Dietzmann, A; Genvresse, I; Grunewald, R; Koschuth, A; Possinger, K; Späth-Schwalbe, E, 2000)
"Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation."6.69Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. ( Bejkos, D; Bischof-Delaloye, A; Chassot, PG; Chiolero, R; Genton, A; Guillou, L; Landry, M; Lejeune, FJ; Leyvraz, PF; Leyvraz, S; Liénard, D; Mirimanoff, RO; Mosimann, F; Pujol, N; Raffoul, W, 2000)
"Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1."6.67Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Bramwell, VH; Dombernowsky, P; Mouridsen, HT; Onsrud, M; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Verweij, J, 1993)
"Ifosfamide dosage was not increased."6.67Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. ( Chevallier, B; Facchini, T; Fargeot, P; Leyvraz, S; Olivier, JP; Vo Van, ML, 1993)
"The results of the association of doxorubicin plus ifosfamide in the treatment of locally advanced and/or metastatic adult soft tissue sarcomas as reported in the literature from 1986 up to the present time are reviewed."6.17Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas. ( Palumbo, R; Santi, L; Sogno, G; Toma, S; Venturino, A, 1992)
"Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios."5.91Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas. ( Alatorre-Alexander, JA; Carrasco-CaraChards, S; Cruz-Zermeño, M; de Jesús Rodríguez-Zea, I; Godina-Flores, A; Green-Renner, D; Guzmán-Casta, J; Guzmán-Huesca, J; Imaz-Olguin, V; Juarez-Vignon Whaley, JJ; Martínez-Barrera, LM; Riera-Sala, R; Rodriguez-Cid, JR; Sánchez-Domínguez, G; Sánchez-Ríos, CP; Santillán-Doherty, PJ; Seidman-Sorsby, A; Sosa-Sánchez, R, 2023)
"CWS/RMS-96 was an international multicenter trial with randomization between two therapy arms of the standard four-drug therapy (vincristine, ifosfamide, adriamycin, dactinomycin [VAIA]) versus an intensified six-drug regimen (carboplatin, epirubicin, vincristine, dactinomycin, ifosfamide, and etoposide [CEVAIE]) for high-risk rhabdomyosarcoma (RMS), extraskeletal Ewing sarcoma (EES), and undifferentiated sarcoma (UDS) in children, adolescents, and young adults aiming to improve their survival."5.51Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults. ( Alaggio, R; Bisogno, G; Casanova, M; Cecchetto, G; Ferrari, A; Kazanowska, B; Klingebiel, T; Koscielniak, E; Kosztyla, D; Ladenstein, R; Ljungman, G; Milano, GM; Niggli, F; Scarzello, G; Sparber-Sauer, M; Vokuhl, C; Zin, A, 2022)
"This randomised phase II/III trial aimed to determine whether perioperative chemotherapy with gemcitabine plus docetaxel (GD) is non-inferior to the standard Adriamycin plus ifosfamide (AI) in terms of overall survival (OS) in patients with soft tissue sarcoma (STS)."5.51Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306. ( Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T, 2022)
"This prospective single-arm phase II clinical trial aimed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) as the first-line treatment for patients with advanced or metastatic soft-tissue sarcoma (STS)."5.51Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study. ( Chen, H; Chen, Y; Huang, M; Jiang, S; Liu, X; Luo, Z; Miao, J; Wang, C; Wang, H; Wang, J; Wu, X; Xia, J; Xu, Y; Yan, W; Yao, W; Yu, L; Zhang, X, 2022)
"Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity."5.37High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011)
"Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990."5.28Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990)
"Patients with high-grade soft tissue sarcomas were treated with 2 cycles of ifosfamide, mitomycin, doxorubicin, and cisplatin plus GM-CSF subcutaneous followed by 45 Gy irradiation with concurrent 2 cycles of mitomycin, doxorubicin, and cisplatin followed by surgery +/- intraoperative radiation or brachytherapy."5.22Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. ( Haddock, M; Mahoney, M; Maples, W; Markovic, SN; O'Connor, MI; Okuno, S; Petersen, I; Shives, T; Sim, F, 2016)
"Doxorubicin and ifosfamide (AI) is standard therapy for high-risk soft tissue sarcoma (STS) but often causes severe toxicities resulting in hospitalisation."5.20A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L, 2015)
"Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role."5.19Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. ( Alcindor, T; Blay, JY; dei Tos, AP; Fisher, C; Gelderblom, H; Hartmann, JT; Hermans, C; Hogendoorn, PC; Hohenberger, P; Judson, I; Kerst, JM; Krarup-Hansen, A; Litière, S; Marreaud, S; Schöffski, P; Sufliarsky, J; van der Graaf, WT; Verweij, J; Whelan, J, 2014)
" Perioperative chemotherapy with adriamycin plus ifosfamide is the current standard treatment for T2bN0M0 high-grade non-round cell soft tissue sarcoma."5.19A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306. ( Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K, 2014)
"The objective of this Phase I dose escalation study was to explore the safety and tolerability of eltrombopag, an oral, nonpeptide, thrombopoietin receptor agonist, in patients with advanced soft tissue sarcoma (STS) and thrombocytopenia due to treatment with doxorubicin and ifosfamide (AI) combination chemotherapy."5.17Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. ( Chawla, SP; Hendifar, A; Kamel, YM; Messam, CA; Patwardhan, R; Staddon, A, 2013)
"This multicenter, phase II trial evaluated the efficacy and safety of everolimus, an mTOR inhibitor, in patients with metastatic or recurrent bone and soft-tissue sarcoma after the failure of anthracycline- and ifosfamide-containing regimens."5.17Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide. ( Ahn, JH; Kim, TM; Kim, YJ; Lee, HJ; Lee, J; Lee, KH; Park, KH; Rha, SY; Yoo, C, 2013)
"Ifosfamide and doxorubicin combination is an active regimen for patients with advanced soft tissue sarcomas (STS) but is burdened by high toxicity."5.15Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. ( Boni, C; Boselli, S; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Frustaci, S; Noberasco, C; Radice, D; Rosati, G; Scalamogna, R; Spitaleri, G; Toffalorio, F; Tucci, A; Vecchio, F, 2011)
"To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma."5.14Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. ( Andrés, R; Balañá, C; Buesa, JM; Casado, A; Cruz, J; Cubedo, R; de la Cruz, JJ; de Las Peñas, R; Del Muro, XG; Fra, J; Gallego, O; Gómez, MA; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Rubió, J; Rubio-Viqueira, B; Sevilla, I, 2009)
"The authors studied a dose-intense regimen of epirubicin and ifosfamide with hypofractionated preoperative radiotherapy for high-risk soft tissue sarcomas."5.13Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas. ( Hayden, JB; Hosenpud, JR; Hung, AY; Mansoor, A; Montag, AG; Mundt, AJ; Peabody, TD; Ryan, CW; Samuels, B; Undevia, S, 2008)
"Perioperative three cycles of full-dose of anthracycline and ifosfamide should be proposed on an individual basis, in reference sarcoma centres, to high-risk localized STS of limbs or trunk-wall in certain histologies."5.12What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma? ( Hindi, N; Martin-Broto, J, 2021)
"Having determined in a phase I study the maximum tolerated dose of high-dose ifosfamide combined with high-dose doxorubicin, we now report the long-term results of a phase II trial in advanced soft-tissue sarcomas."5.12Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. ( Cerny, T; Christinat, A; Dietrich, D; Fey, MF; Guillou, L; Herrmann, R; Honegger, HP; Leyvraz, S; Pestalozzi, B; Sessa, C; Wernli, M, 2006)
"Combinations of high-dose ifosfamide (IF; 10-12 g/m2) plus doxorubicin (DX; 50-90 mg/m2) have been administered to patients with advanced soft tissue sarcoma (ASTS) in an attempt to improve therapeutic efficacy."5.11Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). ( Balañá, C; Buesa, JM; Casado, A; de las Peñas, R; Fra, J; García del Muro, X; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J, 2004)
"The relative value of increasing ifosfamide dose in combination chemotherapy for patients with soft tissue sarcoma (STS) is unclear."5.11Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. ( Baker, LH; Biermann, JS; Chugh, R; Leu, KM; McGinn, CJ; Sondak, VK; Taylor, JM; Worden, FP; Zalupski, MM, 2005)
"To describe the response rate and survival of children and adolescents with unresected or metastatic nonrhabdomyosarcomatous soft tissue sarcomas (NRSTS) treated with vincristine, ifosfamide, and doxorubicin."5.11Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. ( Devidas, M; Gebhardt, M; Grier, HE; Jenkins, J; Marcus, R; Pappo, AS; Pratt, C; Rao, B; Thomas, P, 2005)
"Doxorubicin and ifosfamide are the two most active agents used to treat soft tissue sarcomas."5.11Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas. ( Abe, S; Araki, N; Beppu, Y; Hasegawa, T; Ihara, K; Ishii, T; Isu, K; Kawai, A; Ozaki, T; Sugiura, H; Tsugane, S; Umeda, T; Wada, T; Yabe, H, 2005)
"The aim of this phase II study was to evaluate the efficacy and toxicity of two regimens of ifosfamide in metastatic soft tissue sarcoma patients given as first- and second-line chemotherapy."5.10Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. ( Dombernowsky, P; Hermans, C; Judson, I; Krzemieniecki, K; Mouridsen, HT; Nielsen, OS; Spooner, D; Svancarova, L; Van Glabbeke, M; van Oosterom, AT; Verweij, J, 2002)
"We conducted our study to determine the pharmacokinetics (PK) and clinical efficacy of oral mesna in patients receiving ifosfamide for soft tissue sarcoma."5.10Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. ( Baker, LH; Bernardy, H; Demetri, G; Junge, K; Keohan, ML; Mace, JR; Mueller, U; Niebch, G; Romeis, P; Thoma, A; Wagner, T, 2003)
"Between March 1994 and October 1997, 20 women and 19 men with primary extremity or limb girdle high-grade soft tissue sarcomas were registered to a study of preoperative ifosfamide, mitomycin, doxorubicin, cisplatin (IMAP) plus granulocyte macrophage-colony-stimulating factor (GM-CSF) followed by preoperative irradiation and subsequent limb-sparing surgery."5.10Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. ( Buckner, JC; Edmonson, JH; Foo, ML; Gunderson, LL; Haddock, MG; Mahoney, MR; Maples, WJ; O'Connor, MI; Petersen, IA; Pritchard, DJ; Rock, MG; Shives, TC; Sim, FH; Stafford, SL, 2002)
"Twenty-four patients with soft tissue or bone sarcoma who were treated with high dose ifosfamide-based chemotherapy were enrolled in this study."5.09Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma. ( Akbulut, H; Demirkazik, A; Dinçol, D; Içli, F; Onur, H; Pamir, A; Samur, M; Sencan, O; Senler, FC; Yalçin, B, 2000)
"This study investigated the population pharmacokinetics of ifosfamide in 15 patients treated for soft tissue sarcoma with 9 or 12 g m-2 ifosfamide by means of a 72 h continuous i."5.09Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. ( Beijnen, JH; Huitema, AD; Keizer, HJ; Kerbusch, T; Mathôt, RA; Ouwerkerk, J; Schellens, JH, 2000)
"The Soft Tissue and Bone Sarcoma Group (STBSG) of the EORTC ran a phase II study to assess the therapeutic activity of high-dose ifosfamide in patients with advanced soft tissue sarcomas by means of response rate (RR)."5.09Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group. ( Gwyther, SJ; Judson, IR; Nielsen, OS; van Glabbeke, M; Verweij, J, 2000)
"The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)."5.09A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001)
"The Epirubicin (EPI) and ifosfamide (IFO) combination has been widely tested in soft tissue sarcomas, even though the optimal schedule of drug administration has still to be defined."5.09Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules. ( Cognetti, F; Nardoni, C; Pacetti, U; Papaldo, P; Serrone, L; Zeuli, M, 2001)
"Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study."5.09Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001)
" ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma."5.09Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001)
"The Intergroup Rhabdomyosarcoma Study (IRS) initiated an escalating-dose cyclophosphamide (Cyc) pilot without hematopoietic growth factor (HGF) support in combination with vincristine (Vcr) and actinomycin-D (Amd), known as VAC, to establish a Cyc dose with myelotoxicity comparable to an ifosfamide (Ifos), Vcr, and Amd combination regimen (VAI)."5.08Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response. ( Gehan, E; Maurer, H; Newton, WA; Ruymann, FB; Vietti, T; Wharam, M; Wiener, E, 1995)
"This two-arm, double-blind, randomized trial was conducted to determine the effects of lenograstim, a glycosylated recombinant human granulocyte colony-stimulating factor (rHu-G-CSF), on the hematologic tolerance of patients with sarcoma treated with mesna, doxorubicin, ifosfamide, and doxorubicin (MAID) chemotherapy."5.08Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. ( Bonichon, F; Bui, BN; Chevallier, B; Chevreau, C; Cupissol, D; Fargeot, P; Krakowski, I; Maugard-Louboutin, C; Peny, AM; Thyss, A, 1995)
"Ifosfamide, an oxazaphosphorine analogue, is now commonly used in first-line anthracycline-containing regimens for advanced soft tissue sarcomas, based on its demonstrated single-agent activity in previously treated patients."5.08High-dose ifosfamide in the treatment of advanced soft tissue sarcomas. ( Tursz, T, 1996)
"Ten patients (three males and seven females) were treated for sarcoma with high-dose ifosfamide (IFO) according to a 4 g/m2 1 h i."5.08Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. ( Lokiec, F; Santoni, J; Tubiana-Hulin, M; Weill, S, 1996)
"Ifosfamide is one of the most efficient antimitotic in soft tissue sarcoma."5.08[High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients]. ( Baranzelli, MC; Deligny, N; Demaille, MC; Gourmel, B; N'Guyen, M; Pichon, F, 1997)
"To evaluate the efficacy and feasibility of high-dose ifosfamide (HDI) at a total dose of 14 g/m2 per cycle with mesna in combination with granulocyte colony-stimulating factor (G-CSF) in adult patients with sarcomas."5.08High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. ( Benjamin, RS; Burgess, MA; Hays, C; Papadopolous, N; Patel, SR; Plager, C; Vadhan-Raj, S, 1997)
"The purpose of this study was to evaluate tumour response and toxicity to ifosfamide and continuous infusion etoposide in metastatic or locally advanced soft tissue sarcoma, with dose escalations under G-CSF (granulocyte colony-stimulating factor) support."5.08Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. ( Alvegård, TA; Erlanson, M; Hannisdal, E; Klepp, R; Monge, OR; Raabe, N; Saeter, G; Söderberg, M; Solheim, OP; Strander, H; Turesson, I; Wist, E, 1997)
"Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent."5.08Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. ( Antimi, M; Gatti, C; Palmeri, S; Palumbo, R; Raffo, P; Toma, S; Villani, G, 1997)
"The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses < or = 10 g/m2 show remissions when exposed to high-dose ifosfamide (HDI) (i."5.08Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) ( Antón, A; Arranz, F; Bellmunt, J; Buesa, JM; Casado, A; Escudero, P; García del Muro, J; López-Pousa, A; Martín, J; Menéndez, D; Poveda, A; Valentí, V, 1998)
"Ifosfamide and doxorubicin are the most active agents in the treatment of sarcomas and are characterized by a marked dose-response relationship."5.08Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998)
"Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship."5.08High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? ( Aapro, MS; De Braud, F; De Pas, T; Fazio, N; Goldhirsch, A; Munzone, E; Nolè, F; Orlando, L; Zampino, MG, 1998)
"The purpose of this review is to characterize the nephrotoxicity noted in newly diagnosed patients under 21 years of age after treatment with ifosfamide-containing chemotherapy regimens and local irradiation for localized gross residual rhabdomyosarcoma or undifferentiated sarcoma."5.07Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor. ( Ensign, LG; Foreman, J; Khan, F; Maurer, H; Newton, W; Ortega, J; Ragab, A; Raney, B; Wharam, M; Wiener, E, 1994)
"5 g/m2 mesna was administered for 7 days, both by continuous infusion, in combination with 50 mg/m2/d oral etoposide for 8 days in 21 patients with sarcomas or other solid tumors."5.07Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. ( Hamdan, H; Skubitz, KM; Thompson, RC, 1993)
"To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients."5.07Epirubicin and ifosfamide in advanced soft tissue sarcomas. ( Buonadonna, A; Carbone, A; Crivellari, D; De Paoli, A; Foladore, S; Frustaci, S; Monfardini, S; Morassut, S; Sorio, R, 1993)
"This three-armed phase III study in adults with advanced soft tissue sarcomas was planned as a comparison of objective regression rates, toxicity, and survival of patients receiving doxorubicin alone, ifosfamide plus doxorubicin, and mitomycin plus doxorubicin plus cisplatin."5.07Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. ( Blum, RH; Brooks, JS; Edmonson, JH; Frytak, S; Parkinson, DR; Ryan, LM; Shiraki, M, 1993)
"Doxorubicin alone or with dacarbazine (DTIC; AD) is considered the best available therapy for metastatic adult sarcomas."5.07An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. ( Antman, K; Balcerzak, SP; Barlogie, B; Cooper, RM; Crowley, J; Elias, A; Natale, RB; Rivkin, SE; Trump, DL; Weiss, GR, 1993)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft-tissue sarcoma."5.07Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Steward, W; Thomas, D; van Oosterom, AT; Verweij, J, 1993)
"A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna."5.07Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. ( Azzarelli, A; Casali, P; Fissi, S; Montalto, F; Quagliuolo, V; Santoro, A, 1993)
"The Southwest Oncology Group (SWOG) performed a phase II trial of a combination of ifosfamide/mesna/cisplatin in patients with metastatic soft-tissue sarcoma who had previously received one chemotherapeutic regimen."5.07Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. ( Balcerzak, SP; Budd, GT; Fabian, C; Metch, B; Stephens, RL; Weick, JK; Weiss, SA, 1993)
"On the basis of ifosfamide's demonstrated single-agent activity in adult soft-tissue sarcoma, the Eastern Cooperative Oncology Group (ECOG) tested whether ifosfamide would add to the efficacy of doxorubicin in a three-regimen, controlled phase III trial."5.07Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. ( Blum, RH; Edmonson, J; Pelletier, L; Ryan, L, 1993)
"A total of 37 adult patients with locally advanced or metastatic soft-tissue sarcoma (STS) entered a pilot study of combination chemotherapy based on the CYVADIC (cyclophosphamide, vincristine, doxorubicin, and dacarbazine) regimen, in which cyclophosphamide was replaced by ifosfamide and mesna (1 g/m2 ifosfamide given daily on days 1-5 as 2-h infusions, 1."5.07Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma. ( Blomqvist, CP; Elomaa, I; Virolainen, M; Wiklund, TA, 1992)
"Doxorubicin and ifosfamide are the two most active agents used in the treatment of advanced inoperable soft-tissue sarcoma, but their use in combination produces dose-limiting myelosuppression."5.07Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Blackledge, G; Clavel, M; Greifenberg, B; Soedirman, J; Somers, R; Steward, WP; Thomas, D; Van Glabbeke, M; Van Oosterom, AT; Verweij, J, 1991)
"European and American investigators have reported response rates of 38% to 83% for ifosfamide alone in pretreated sarcomas."5.06Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. ( Antman, KH; Elias, A; Grier, HE; Ryan, L; Sherman, D, 1989)
"In this phase II trial, 105 eligible patients with no prior chemotherapy and advanced sarcoma received doxorubicin, ifosfamide, and dacarbazine (DTIC) with mesna uroprotection (MAID)."5.06Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. ( Aisner, J; Antman, KH; Collins, J; Elias, A; Ryan, L; Sulkes, A, 1989)
"One hundred and seventy-one patients with advanced soft tissue sarcoma entered a randomized crossover phase II study comparing cyclophosphamide (CYCLO) with a new analogue, ifosfamide (IFOS), both administered as 24 h i."5.06Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. ( Blackledge, G; Bramwell, VH; Mouridsen, HT; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Van Oosterom, A, 1986)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."4.91Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2015)
"The authors report a retrospective analysis of high-dose ifosfamide, carboplatin, and etoposide (HD-ICE) for patients with refractory or relapsed neuroblastoma (NB)."4.89Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. ( Basu, EM; Cheung, NK; Kramer, K; Kushner, BH; Modak, S; Roberts, SS, 2013)
" The BSTTSG has currently been conducting a Phase III trial, JCOG 0905, to investigate the superiority of the addition of ifosfamide to the standard chemotherapy with methotrexate, cisplatin and doxorubicin for operable, high-grade osteosarcoma."4.88The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. ( Iwamoto, Y; Tanaka, K, 2012)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."4.88Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2012)
"Independent favourable prognostic factors for overall survival (OS) were good performance status, female gender, low histological grade, extremity primary tumour site and locally advanced disease; for progression-free survival (PFS), the combination of doxorubicin and ifosfamide, locally advanced disease, and tumour entity with a lower risk to progress for synovial sarcoma patients compared to leiomyosarcoma."4.86Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr ( Blay, JY; Hogendoorn, PC; Krarup-Hansen, A; Le Cesne, A; Ouali, M; Rodenhuis, S; Sleijfer, S; van Glabbeke, M; Verweij, J, 2010)
"Ifosfamide is a chemotherapeutic prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma."4.86Palifosfamide, a bifunctional alkylator for the treatment of sarcomas. ( Jung, S; Kasper, B, 2010)
"Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma."4.86Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients. ( Kremer, LC; Langer, T; Mulder, RL; Paulides, M; van Dalen, EC, 2010)
" Therefore, gemcitabine should be considered as the best option after doxorubicin failure in leiomyosarcoma patients."4.86[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines]. ( Bui-Nguyen, B; Italiano, A; Toulmonde, M, 2010)
"The current study was performed to evaluate the toxicity profile of therapeutic doses of ifosfamide (IFX) given concurrently with full-dose external beam radiotherapy (EBRT) in patients with soft tissue and bone sarcomas."4.81Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma. ( Ballo, MT; Benjamin, RS; Burgess, MA; Cormier, JN; Feig, BW; Herzog, CE; Hunt, KK; Patel, SR; Pisters, PW; Raney, RB; Zagars, GK, 2001)
"Ifosfamide is an alkylating agent with clinical activity in the treatment of sarcomas, and data support a dose-response relationship in this disease."4.79High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. ( Demetri, GD, 1996)
"We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985."4.78Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993)
"Doxorubicin and ifosfamide are currently the two main drugs for the treatment of soft tissue sarcomas in adults."4.78Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. ( Azzarelli, A; Bertulli, R; Casali, P; Devizzi, L; Pastorino, U; Santoro, A; Zucchinelli, P, 1993)
" The most active single agents against osteosarcoma are doxorubicin (overall response rate, 21%), methotrexate (30% to 40%), cisplatin (25%), and ifosfamide (28%)."4.78Chemotherapy of advanced sarcomas of bone and soft tissue. ( Antman, KH, 1992)
"Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas."4.78The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990)
"The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas."4.77The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989)
"The most active single agents in soft-tissue sarcomas are doxorubicin (Adriamycin) and ifosfamide, with response rates of 20-35%."4.77Chemotherapy of advanced soft-tissue sarcomas. ( Antman, KH; Elias, AD, 1988)
"We conducted a multi-institutional retrospective study, identifying sarcoma patients who received anthracyclines and/or ifosfamide during pregnancy."4.12Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy. ( Agulnik, M; Davis, LE; Godbole, S; Hirbe, AC; Livingston, JA; Miller, D; Park, Y; Parkes, A; Posey, K; Robinson, SI; Skubitz, K; Van Tine, BA, 2022)
"To investigate the value of contrast-enhanced computed tomography (CECT) radiomics features in predicting the efficacy of epirubicin combined with ifosfamide in patients with pulmonary metastases from soft tissue sarcoma."4.12Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features. ( Jiang, X; Li, M; Ma, ST; Miao, L; Wang, YM; Zhang, HH, 2022)
"To compare long-term outcomes of high-grade, primary soft-tissue-sarcoma (STS), using Ifosfamide-Doxorubicin vs local therapy alone, in histology-specific sarcomas."4.02The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience. ( Burchette, RJ; Goy, BW; Helmstedter, CS; Padmanabhan, A; Syed, S, 2021)
"The usefulness of adjuvant chemotherapy for high-grade osteosarcoma was established by two randomized, controlled trials conducted in the 1980s, which used six drugs, doxorubicin, cisplatin, high-dose methotrexate, bleomycin, cyclophosphamide and actinomycin D."4.02Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group. ( Hiraga, H; Ozaki, T, 2021)
"We compared the outcomes in soft tissue sarcoma (STS) treated with olaratumab and doxorubicin (OD) versus doxorubicin, ifosfamide, and mesna (AIM) to assess whether OD could supersede AIM in STS therapy."3.96Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas. ( Copeland, VC; Cranmer, LD; Hammer, KJ; Loggers, ET; Pollack, SM; Wagner, MJ, 2020)
"A retrospective search of the Royal Marsden Sarcoma Unit Database was performed to identify patients initially treated with ifosfamide (as single agent or in combination) and who were subsequently rechallenged with single-agent ifosfamide."3.88Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. ( Benson, C; Constantinidou, A; Jones, RL; Judson, I; Messiou, C; Miah, A; Noujaim, J; Thway, K, 2018)
"We retrospectively reviewed outcomes of treatment with VIP (combination of etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma (STS)."3.85VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. ( Baek, SW; Choi, YS; Jo, DY; Kim, S; Lee, HJ; Moon, JY; Ryu, H; Song, IC; Yun, HJ, 2017)
"The combination of topotecan and cyclophosphamide is active in relapsed Ewing sarcoma family of tumors (ESFT)."3.83Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group. ( Bond, MC; Felgenhauer, JL; Femino, JD; Gorlick, R; Krailo, MD; Laack, NN; Marina, N; Mascarenhas, L; Meyer, J; Ranganathan, S; Villaluna, D; Womer, RB, 2016)
"5%) nonmetastatic soft tissue sarcoma received neoadjuvant chemoradiotherapy with ifosfamide (1."3.83Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience. ( Agaimy, A; Croner, R; Fietkau, R; Hohenberger, W; Lettmaier, S; Ott, O; Semrau, S; Stubbe, F; Vassos, N, 2016)
"A 67-year-old male patient developed progressive renal failure following successful treatment of a soft tissue sarcoma that comprised surgical resection after neoadjuvant radiochemotherapy with the application of doxorubicin (cumulative dose 180 mg/m²) and ifosfamide (cumulative dose 33 g/m²)."3.80[End-stage renal disease after sarcoma therapy - case 3/2014]. ( Amann, K; Artunc, F; Bakos, G; Baumann, D; Bunz, H; Ciarimboli, G; Kluba, T; Kopp, HG; Müller, M; Schlatter, E; Steinke, I; Weyrich, P, 2014)
"Our data suggest that multimodal treatment with ifosfamide and/or locoregional hyperthermia in combination with neoadjuvant radiotherapy might improve outcome in high-risk soft tissue sarcomas."3.79Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas. ( Bamberg, M; Eckert, F; Gani, C; Kluba, T; Kopp, HG; Mayer, F; Müller, AC; Zips, D, 2013)
"Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9."3.79Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma. ( Badalamenti, G; Bronte, G; Fulfaro, F; Incorvaia, L; Leto, G; Maltese, G; Provenzano, S, 2013)
" Doxorubicin should be administered preferably as 3-weekly bolus injections at doses higher than 60 mg/m2 because of its dose-response relationship."3.76The treatment of soft tissue sarcomas with focus on chemotherapy: a review. ( Pinedo, HM; Verweij, J, 1986)
"Twenty-three children and adolescents with metastatic sarcomas received vincristine, doxorubicin, cyclophosphamide, ifosfamide, sodium mercaptoethanesulfonate (mensa), and etoposide (VACIME) chemotherapy, consisting of 8 courses of vincristine 2 mg/m(2) on Day 0, doxorubicin 37."3.71Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. ( Douglas, J; Felgenhauer, J; Gooley, T; Hawkins, DS; Kreissman, S; Park, J; Pendergrass, TW; Rowley, SD; Sanders, JE; Thomson, B, 2002)
"Adriamycin, dacarbazine and ifosfamide are three effective chemotherapy drugs in treating progressive soft tissue sarcoma."3.71[Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma]. ( Chen, LK; Liang, Y; Liu, JL; Teng, XY; Xu, GC; Zhou, XM, 2002)
"Ifosfamide is a leading drug in soft tissue sarcoma therapy."3.70Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998)
"High-dose ifosfamide (HD-IFX) has shown significant antitumor activity in advanced sarcoma and breast carcinoma."3.69Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. ( Albanell, J; Baselga, J; Bellmunt, J; Casado, S; Eres, N; Ribas, A, 1997)
"From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)."3.69[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997)
"This study was designed to test the feasibility of administering doxorubicin at an optimal dose-intensity (> 70 mg/m2 per 21 days) in combination with ifosfamide under recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) cover in patients with metastatic soft tissue sarcomas."3.68Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Grou ( Clavel, M; Crowther, D; Kerbrat, P; Rouesse, J; Somers, R; Spooner, D; Steward, WP; Tueni, E; Tursz, T; Verweij, J, 1993)
"A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects."3.68[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993)
"Between 1982 and 1986, 38 patients with soft-tissue sarcomas were treated with the combination doxorubicin/dacarbazine (group A); between 1986 and 1990, another 46 patients received doxorubicin/ifosfamide (group B); and between 1990 and 1991, 11 patients received an alternating regimen of doxorubicin and ifosfamide (group C)."3.68Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. ( Agarwal, K; Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Zornig, C, 1993)
"Two trials using ifosfamide-based combination chemotherapy for advanced soft-tissue sarcoma have been completed."3.68Ifosfamide combination regimens for soft-tissue sarcoma. ( Bell, DR; Dalley, D; Levi, J; Simes, RJ; Stuart-Harris, R; Wiltshaw, E, 1993)
"The response of ifosfamide-based chemotherapeutic regimens was retrospectively analyzed in adult patients with advanced soft-tissue sarcoma who were treated at the West German Tumor Center, Essen, between 1978 and 1990."3.68Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. ( Kellner, R; Schütte, J; Seeber, S, 1993)
"Currently, anthracyclines and ifosfamide are the most effective drugs for the treatment of disseminated soft-tissue sarcoma."3.68A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults. ( Anagnou, J; Bokemeyer, C; Harstrick, A; Knipp, H; Köhne-Wömpner, CH; Neumann, S; Poliwoda, H; Schmoll, HJ; Schöffski, P; Wipperman, B, 1993)
"A total of 46 consecutive patients were entered into this study to assess the efficacy and toxicity of an epirubicin/ifosfamide combination in treating locally advanced and/or metastatic adult sarcomas (38 soft-tissue sarcomas and 7 bone sarcomas in 45 evaluable patients)."3.68Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas. ( Albanese, E; Barisone, A; Canavese, G; Cantoni, E; Palumbo, R; Reggiardo, G; Rosso, R; Santi, L; Toma, S, 1993)
"We gave the "optimal" dose of doxorubicin (75 mg/m2) with ifosfamide (5 g/m2), the two most active agents against metastatic soft-tissue sarcomas, in an attempt to determine the feasibility of administration of these doses in combination."3.68The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. ( Clavel, M; Crowther, D; Kerbrat, P; Rouesse, J; Somers, R; Spooner, D; Steward, WP; Tueni, E; Tursz, T; Verweij, J, 1993)
"Twenty-eight patients with non-pretreated metastatic soft tissue sarcomas were entered on a treatment protocol of rapidly alternating epirubicin/dacarbazine and ifosfamide: Epirubicin 100 mg/m2 d1, dacarbazine 500 mg/m2 d1 + d2, ifosfamide 6000 mg/m2 24-h infusion d15; repeated d29."3.68Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas. ( Bokemeyer, C; Harstrick, A; Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöffski, P, 1992)
"From July 1986 to July 1989, 40 patients (92% pretreated) with deep-seated, advanced soft tissue sarcomas (STS, 25 patients), Ewing's sarcomas (ES, eight patients), osteosarcomas (OS, three patients) and chondrosarcomas (ChS, four patients) were treated at the University of Munich in a protocol involving regional hyperthermia (RHT) combined with ifosfamide plus etoposide."3.68Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study. ( Berger, H; Boehm, E; Denecke, H; Issels, RD; Jauch, KW; Nagele, A; Peter, K; Prenninger, SW; Sauer, H; Wilmanns, W, 1990)
"The objective of this phase II trial was to assess the therapeutic activity and toxicity of doxorubicin plus ifosfamide in previously untreated patients with advanced soft tissue sarcoma."3.68Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Dombernowsky, P; Mouridsen, HT; Santoro, A; Schütte, J; Somers, R; Stewart, W; Thomas, D; van Oosterom, AT; Verweij, J, 1990)
"Forty-three adult patients with locally advanced or metastatic soft tissue sarcoma entered a pilot study of combination chemotherapy comprising 50 mg of doxorubicin/m2 by intravenous bolus, 850 mg of dacarbazine/m2 by 1-hour infusion, and 5 g of ifosfamide/m2 by 24-hour infusion with mesna uroprotection."3.67Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group. ( Bramwell, V; Eisenhauer, E; Knowling, M; Quirt, I; Verma, S; Warr, D; Young, V, 1989)
"Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients."3.67Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986)
"Fifty-four patients with advanced soft tissue sarcoma were treated with a combination of ifosfamide (5 g/m2) and adriamycin (40-60 mg/m2) at 3 weekly intervals."3.67A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. ( Fisher, C; King, M; MacMillan, S; Mansi, JL; Stuart-Harris, R; Wiltshaw, E, 1988)
"We have evaluated the activity of ifosfamide in 75 patients with recurrent sarcomas and pediatric solid tumors."3.67A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. ( Arasi, V; Magrath, I; Miser, J; Raynor, A; Rosenberg, S; Sandlund, J, 1986)
" Hemorrhagic cystitis was not observed in patients treated with 400-500 mg of mesna iv every 4 hours during ifosfamide treatment."3.67Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. ( Antman, KH; Montella, D; Rosenbaum, C; Schwen, M, 1985)
"In a phase II study, 42 patients with advanced soft-tissue sarcoma were treated with ifosfamide by 24-h infusion and mesna by 4-h IV bolus, repeated every 3 weeks."3.66High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. ( Gowing, NF; Harper, PG; Kaye, SB; Mooney, CA; Parsons, CA; Stuart-Harris, RC; Wiltshaw, E, 1983)
"The value of neoadjuvant chemotherapy in soft tissue sarcoma (STS) is not completely understood."3.11Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. ( Bagué, S; Bianchi, G; Blay, JY; Braglia, L; Brunello, A; Bruzzi, P; Casali, PG; Coindre, JM; Dei Tos, AP; Diaz-Beveridge, R; Donati, DM; Ferraresi, V; Fontana, V; Grignani, G; Gronchi, A; Infante, G; Lopez-Pousa, A; Lugowska, I; Marchesi, E; Marrari, A; Martin-Broto, J; Merlo, DF; Miceli, R; Morosi, C; Palassini, E; Palmerini, E; Pasquali, S; Picci, P; Quagliuolo, V; Stacchiotti, S; Tendero, O, 2022)
"The therapy of high-risk soft tissue sarcomas (STS) remains an interdisciplinary challenge."3.01Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review. ( Ademaj, A; Corradini, S; Eckert, F; Flörcken, A; Ghadjar, P; Issels, R; Kaul, D; Lindner, LH; Oberacker, E; Ott, OJ; Pink, D; Potkrajcic, V; Reichardt, P; Riesterer, O; Roohani, S; Spalek, MJ; Veltsista, PD; Zips, D, 2023)
"The value of chemotherapy in soft tissue sarcoma (STS) remains controversial."2.94Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial. ( Cabarrou, B; Chevreau, C; Chibon, F; Filleron, T; Le Guellec, S; Lesluyes, T; Lodin, S; Massoubre, A; Mounier, M; Poublanc, M; Valentin, T, 2020)
"Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment."2.87Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. ( Abdel-Rahman, S; Angele, M; Belka, C; Daugaard, S; Dürr, HR; Ghadjar, P; Gronchi, A; Hiddemann, W; Hohenberger, P; Issels, RD; Jauch, KW; Knösel, T; Lindner, LH; Mansmann, U; Mella, O; Reichardt, P; Salat, C; Schmidt, M; Verweij, J; Vujaskovic, Z; Wessalowski, R; Wust, P, 2018)
"Patients <30 years old with Ewing sarcoma were eligible."2.80Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1. ( Abujamra, AL; Almeida, MT; Benites, E; Boldrini, E; Brunetto, AL; Castillo, LA; Costa, C; Gadelha, A; Gregianin, LJ; Kirst, D; Macedo, CD; Morais, V; Nakasato, A; Pereira, WV; Petrilli, AS; Pizza, M; Rodriguez-Galindo, C; Watanabe, FM, 2015)
"The role of chemotherapy in high-risk soft tissue sarcoma is controversial."2.76A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. ( Bischof, M; Dietrich, S; Dimitrakopoulou-Strauss, A; Egerer, G; Ho, AD; Kasper, B; Lehner, B; Mechtersheimer, G; Roeder, F; Schmitt, T; Strauss, LG; Wuchter, P, 2011)
" A novel five-drug combination of etoposide, vincristine, dactinomycin, ifosfamide, and doxorubicin (EVAIA) was evaluated for high-risk patients, but cumulative chemotherapy dosage and treatment duration were reduced for the remaining individuals as compared with that of the previous trial CWS-86."2.74Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. ( Bielack, SS; Brecht, I; Dantonello, TM; Dickerhoff, R; Gadner, H; Greiner, J; Greulich, M; Harms, D; Herbst, M; Int-Veen, C; Juergens, H; Kirsch, S; Klingebiel, T; Koscielniak, E; Leuschner, I; Marky, I; Scheel-Walter, HG; Schmelzle, R; Schmidt, BF; Treuner, J, 2009)
"To compare the radiological criteria RECIST, WHO, and tumor volume for evaluation of tumor response in patients with soft tissue sarcomas (STS) showing either good or poor pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia, and to examine the dependence of the findings on the applied thermal dose."2.74Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS). ( Abdel-Rahman, S; Issels, RD; Lindner, LH; Reiser, MF; Santl, M; Stahl, R; Wang, T, 2009)
"Ifosfamide is a chemotherapeutic agent that requires cytochrome P450 3A (CYP3A) for bioactivation and metabolism."2.73Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. ( Baker, LH; Chugh, R; Griffith, KA; Leu, KM; Taylor, JM; Thomas, DG; Wagner, T; Worden, FP; Zalupski, MM, 2007)
"Prognosis of patients with metastatic soft tissue sarcomas (MSTS) is poor even after response to doxorubicin-based chemotherapy."2.72Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas. ( Abdel-Rahman, S; Baumert, J; Falk, M; Hentrich, M; Hiddemann, W; Issels, RD; Licht, T; Salat, C; Schlemmer, M; Straka, C; Wendtner, CM, 2006)
"Grade 3 thrombocytopenia was observed in five cases (36%)."2.71Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report. ( Kitamura, T; Kume, H; Matsumoto, S; Nishimatsu, H; Okamoto, N; Suzuki, M; Takahashi, S; Tomita, K, 2005)
"Adjuvant chemotherapy for soft tissue sarcoma is controversial because previous trials reported conflicting results."2.70Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. ( Apice, G; Azzarelli, A; Barbieri, E; Bonetti, M; Buonadonna, A; Comandone, A; De Paoli, A; Frustaci, S; Gherlinzoni, F; Olmi, P; Picci, P; Pignatti, G; Serraino, D; Zmerly, H, 2001)
"Etoposide monotherapy was successful in 8%; the effectiveness of cisplatin was 5-23%."2.69The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. ( Bodoky, G; Eckhardt, S; Láng, I; Pápai, Z; Poller, I; Rahóty, P; Szántó, J; Szendroi, M, 2000)
"Gemcitabine was administered as a 360 min infusion on days 1, 8 and 15 of a 28 day cycle."2.69Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas. ( Dietzmann, A; Genvresse, I; Grunewald, R; Koschuth, A; Possinger, K; Späth-Schwalbe, E, 2000)
"Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation."2.69Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. ( Bejkos, D; Bischof-Delaloye, A; Chassot, PG; Chiolero, R; Genton, A; Guillou, L; Landry, M; Lejeune, FJ; Leyvraz, PF; Leyvraz, S; Liénard, D; Mirimanoff, RO; Mosimann, F; Pujol, N; Raffoul, W, 2000)
"Ifosfamide (5 g/m2) was compared with its parent analogue cyclophosphamide (1."2.67Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. ( Blackledge, G; Bramwell, VH; Dombernowsky, P; Mouridsen, HT; Onsrud, M; Santoro, A; Somers, R; Sylvester, R; Thomas, D; Verweij, J, 1993)
"Ifosfamide dosage was not increased."2.67Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study. ( Chevallier, B; Facchini, T; Fargeot, P; Leyvraz, S; Olivier, JP; Vo Van, ML, 1993)
"Patients with localized high-risk soft tissue sarcoma are at high risk for both local recurrence and distant metastases despite optimal surgical treatment."2.61[Multimodal treatment of sarcomas: standards and new aspects in pharmacological and radio-oncological treatment]. ( Lindner, LH, 2019)
"Localized soft tissue sarcoma may be cured with complete tumor excision, but overall, outcomes are sub-optimal."2.58Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy. ( Charlson, J, 2018)
"Soft tissue sarcomas are rare tumours in adults and therefore require a multidisciplinary approach for optimal management."2.47Systemic management strategies for metastatic soft tissue sarcoma. ( Movva, S; Verschraegen, C, 2011)
"Synovial sarcoma is a malignant soft-tissue neoplasm, usually arising in close association with the joints and generally carrying a poor prognosis."2.43Bilateral metastatic renal synovial sarcoma. ( Matin, SF; Pollock, RE; Stage, AC, 2005)
"Soft tissue sarcomas are a heterogeneous group of malignancies arising from mesenchymal tissues."2.42Emerging treatments for soft tissue sarcoma of adults. ( Fahn, W; Issels, RD, 2004)
"Extraskeletal Ewing's sarcoma (EES) is rare and has not been previously described about the cervical spine."2.41Extraskeletal Ewing's sarcoma: a case report and review of the literature. ( Caulfield, R; Eustace, S; Fennelly, DJ; Hurson, B; Kennedy, JG; O'Rourke, KS, 2000)
"The first chemotherapy study of soft tissue sarcoma (STS) by the Scandinavian Sarcoma Group was started in 1981 (SSG I)."2.40Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience. ( Alvegård, TA; Fernberg, JO; Hall, KS; Monge, O; Saeter, G; Strander, H; Wiklund, T, 1999)
"The role of chemotherapy for soft tissue sarcoma with the exception of rhabdomyosarcoma remains controversial."2.38[Chemotherapy for soft tissue sarcoma--current concepts and review]. ( Hatakeyama, K; Ishii, T; Umeda, T; Wakita, H, 1993)
"Sarcomas are a relatively rare and heterogeneous group of malignant tumors of principally mesenchymal origin."2.38The clinical management of soft tissue sarcomas. ( Elias, AD, 1992)
"Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios."1.91Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas. ( Alatorre-Alexander, JA; Carrasco-CaraChards, S; Cruz-Zermeño, M; de Jesús Rodríguez-Zea, I; Godina-Flores, A; Green-Renner, D; Guzmán-Casta, J; Guzmán-Huesca, J; Imaz-Olguin, V; Juarez-Vignon Whaley, JJ; Martínez-Barrera, LM; Riera-Sala, R; Rodriguez-Cid, JR; Sánchez-Domínguez, G; Sánchez-Ríos, CP; Santillán-Doherty, PJ; Seidman-Sorsby, A; Sosa-Sánchez, R, 2023)
"Treatment of highly malignant soft tissue sarcomas (STSs) requires multicomponent therapy including surgery, radiotherapy, and chemotherapy."1.91Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy. ( Anastasia, TA; Belitsky, GA; Bokhyan, BY; Fetisov, TI; Khazanova, SA; Kirsanov, KI; Lovenger, AA; Marshall, VI; Rogozhin, DV; Shtompel, PA; Trapeznikova, ES; Yakubovskaya, MG; Zinovieva, VY, 2023)
"However, because sarcoma is very rare, there is little evidence regarding the management of elderly patients with sarcoma."1.72Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. ( Ozaki, T; Tanaka, K, 2022)
"Pancreatic Ewing's sarcoma is not reported commonly, with inconsistent clinical manifestations."1.72Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report. ( Chan, WT; Hou, JY; Jiang, CB; Lee, HC; Liu, HC; Liu, YC; Sheu, JC; Wu, PS; Yeh, TC; Yeung, CY, 2022)
"Liposarcoma is very rare in female genital tract, and more rare for dedifferentiated liposarcoma in gynecologic field."1.62Primary dedifferentiated Liposarcoma of vagina: a first case report. ( Shen, Y; Xie, C, 2021)
"Myxofibrosarcoma is an aggressive soft tissue neoplasm, classified as a variant of malignant fibrous histiocytoma."1.46A rare presentation of myxofibrosarcoma as a Pancoast tumor: a case report. ( Abboud, A; Chedrawy, EG; Hussain, Z; Jevremovic, V; Yousuf, A, 2017)
"On multivariate analysis, positive surgical margins negatively impacted LRC, DFS, and OS (hazard ratio [HR]=10."1.43The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome. ( Benedetto, P; Conway, S; Dosch, A; Fernandez, G; Kwon, D; Mahmoud, O; Pitcher, JD; Temple, HT; Trent, J; Wolfson, AH, 2016)
"Extraosseous osteosarcoma is rare, and the most appropriate therapy is unclear because there are few studies regarding its treatment."1.42Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas? ( Fan, Z; Guadagnolo, BA; Lewis, VO; Lin, PP; Patel, S, 2015)
"Soft tissue sarcomas are a heterogeneous group of malignant tumors."1.40Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas. ( Cheng, EY; Clohisy, DR; Manivel, JC; O'Donnell, PW, 2014)
"Alveolar soft part sarcomas are rarely seen and highly malignant tumors, and the prognosis of stage IV ASPS is poor."1.38[Treatment and prognosis of stage IV alveolar soft part sarcoma]. ( Yang, Y; Zhao, J, 2012)
"Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity."1.37High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011)
"Soft tissue sarcoma is a malignant connective tissue tumor that may arise anywhere in the body and from diverse mesenchymal elements."1.35Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? ( Patel, S; Schuetze, SM, 2009)
"The response of adult soft tissue sarcoma (STS) to chemotherapy is uncertain."1.34[Responses of 109 adult soft tissue sarcoma patients to chemotherapy]. ( Guan, ZZ; Huang, HQ; Jiang, WQ; Li, FH; Lin, TY; Luo, HY; Qiu, MZ; Sun, XF; Wang, F; Wang, SS; Xu, F; Xu, GC; Xu, RH, 2007)
"Alveolar soft part sarcoma is a rare malignant tumor with unusual clinical behavior."1.33Alveolar soft part sarcoma: a rare and enigmatic entity. ( Anderson, ME; Gebhardt, MC; Hornicek, FJ; Mankin, HJ; Raskin, KA, 2005)
"Embryonal rhabdomyosarcoma is the most common soft tissue sarcoma of childhood but is rarely seen in adults."1.32Embryonal rhabdomyosarcoma presenting in an adult: a case report and discussion of immunohistochemical staining. ( Barnette, DJ; Feldman, BD; Graham, BS; Hardaway, CA, 2003)
"Thirty-seven patients had distant metastases at presentation."1.32Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. ( Hatano, H; Hotta, T; Kawashima, H; Morita, T; Ogose, A; Ueda, T; Yazawa, Y, 2003)
"In patients with metastatic breast cancer (MBC), early dose intensification with multiple cycles of peripheral blood stem cell-supported high-dose chemotherapy (HDCT) seems superior to a late dose-intensification strategy."1.31Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer. ( Bastert, G; Egerer, G; Goerner, R; Grischke, EM; Haas, R; Hensel, M; Ho, AD; Hohaus, S; Khbeis, T; Schneeweiss, A; Solomayer, E, 2001)
"The role and value of chemotherapy for soft tissue sarcomas remain unclear."1.30[Chemotherapy for pulmonary metastases of soft tissue sarcoma]. ( Kito, M; Umeda, T, 1998)
" A critical question in comparing an experimental treatment to a standard is how much increase in an adverse event rate is an acceptable trade-off for achieving a targeted improvement in efficacy, or vice versa."1.30Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials. ( Cheng, SC; Thall, PF, 1999)
"Ifosfamide is a newly available analog of cyclophosphamide in the oxazaphosphorine drug class."1.28Ifosfamide vs cyclophosphamide in cancer therapy. ( Weiss, RB, 1991)
" We have studied in patients with advanced cancer the feasibility and bioavailability of a subcutaneously administered isotonic and neutral (pH 7) IFO solution given continuously over 10 h for up to 5 days."1.28Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients. ( Brunner, KW; Cerny, T; Küpfer, A; Zeugin, T, 1990)
"Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990."1.28Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990)
"Ifosfamide and mesna were administered to 77 patients with advanced malignancies."1.27Prediction of ifosfamide/mesna associated encephalopathy. ( Blackledge, G; Blake, AE; Honigsberger, L; Kelly, KA; Meanwell, CA, 1986)

Research

Studies (286)

TimeframeStudies, this research(%)All Research%
pre-199032 (11.19)18.7374
1990's94 (32.87)18.2507
2000's70 (24.48)29.6817
2010's60 (20.98)24.3611
2020's30 (10.49)2.80

Authors

AuthorsStudies
Kim, JH1
Kim, SH1
Jeon, MK1
Kim, JE1
Kim, KH1
Yun, KH1
Jeung, HC1
Rha, SY2
Ahn, JH3
Kim, HS1
Benjamin, RS6
Pasquali, S1
Palmerini, E2
Quagliuolo, V6
Martin-Broto, J3
Lopez-Pousa, A6
Grignani, G3
Brunello, A2
Blay, JY5
Tendero, O2
Diaz-Beveridge, R1
Ferraresi, V1
Lugowska, I1
Infante, G1
Braglia, L1
Merlo, DF1
Fontana, V1
Marchesi, E1
Donati, DM1
Palassini, E3
Bianchi, G1
Marrari, A1
Morosi, C2
Stacchiotti, S4
Bagué, S1
Coindre, JM2
Dei Tos, AP5
Picci, P5
Bruzzi, P1
Miceli, R2
Casali, PG5
Gronchi, A7
Fiore, M2
Sambri, A1
Spinnato, P1
Zucchini, R1
Giannini, C1
Caldari, E1
Pirini, MG1
De Paolis, M1
Goy, BW1
Syed, S1
Padmanabhan, A1
Burchette, RJ1
Helmstedter, CS1
Oda, Y2
Tanaka, K5
Hirose, T1
Hasegawa, T2
Hiruta, N1
Hisaoka, M1
Yoshimoto, M1
Otsuka, H1
Bekki, H1
Ishii, T5
Endo, M1
Kunisada, T1
Hiruma, T2
Tsuchiya, H1
Katagiri, H2
Matsumoto, Y2
Kawai, A4
Nakayama, R2
Kawashima, H3
Takenaka, S3
Emori, M2
Watanuki, M2
Yoshida, Y1
Okamoto, T1
Mizusawa, J2
Fukuda, H3
Ozaki, T5
Iwamoto, Y4
Nojima, T1
Acem, I1
van Houdt, WJ1
Grünhagen, DJ1
van der Graaf, WTA1
Rueten-Budde, AJ1
Gelderblom, H2
Verhoef, C1
van de Sande, MAJ1
Miller, D1
Livingston, JA1
Park, Y1
Posey, K1
Godbole, S1
Skubitz, K1
Robinson, SI1
Agulnik, M1
Davis, LE1
Van Tine, BA1
Hirbe, AC1
Parkes, A1
Sparber-Sauer, M1
Ferrari, A3
Kosztyla, D1
Ladenstein, R1
Cecchetto, G1
Kazanowska, B2
Scarzello, G2
Ljungman, G1
Milano, GM1
Niggli, F1
Alaggio, R2
Vokuhl, C1
Casanova, M2
Klingebiel, T3
Zin, A1
Koscielniak, E5
Bisogno, G4
Machida, R1
Tsukushi, S1
Asanuma, K1
Hiraga, H3
Hiraoka, K1
Yonemoto, T2
Abe, S2
Nishida, Y1
Nagano, A1
Suehara, Y1
Kawano, M1
Morii, T1
Hatano, H2
Toguchida, J1
Okuma, T2
Takeyama, M1
Akisue, T1
Furuta, T1
Outani, H2
Yamamoto, T1
Kataoka, T1
Miao, L1
Ma, ST1
Jiang, X1
Zhang, HH1
Wang, YM1
Li, M1
Liu, X1
Jiang, S1
Wang, H1
Wu, X1
Yan, W1
Chen, Y2
Xu, Y1
Wang, C3
Yao, W2
Wang, J2
Yu, L1
Miao, J1
Chen, H1
Xia, J1
Huang, M1
Zhang, X1
Luo, Z1
Han, X1
Li, Q1
Wang, EH1
Liu, N1
Liu, YC3
Yeh, TC3
Wu, PS3
Sheu, JC3
Lee, HC3
Yeung, CY3
Jiang, CB3
Liu, HC3
Hou, JY3
Chan, WT3
Rodriguez-Cid, JR3
Juarez-Vignon Whaley, JJ3
Sánchez-Domínguez, G3
Guzmán-Casta, J3
Carrasco-CaraChards, S3
Guzmán-Huesca, J3
Riera-Sala, R3
Sánchez-Ríos, CP3
Cruz-Zermeño, M3
Seidman-Sorsby, A3
de Jesús Rodríguez-Zea, I3
Alatorre-Alexander, JA3
Martínez-Barrera, LM3
Santillán-Doherty, PJ3
Godina-Flores, A3
Imaz-Olguin, V3
Sosa-Sánchez, R3
Green-Renner, D3
Merjaneh, N1
Kim, H1
Escoto, H1
Metts, J1
Ray, A1
Bukowinski, A1
LeBlanc, Z1
Fair, D1
Watanbe, M1
Alva, E1
Todd, K1
Daley, J1
Hartt, D1
Cramer, SL1
Szabo, S1
Pressey, JG1
Gutierrez-Sainz, L1
Martinez-Fdez, S1
Pedregosa-Barbas, J1
Peña, J1
Alameda, M1
Viñal, D1
Villamayor, J1
Martinez-Recio, S1
Perez-Wert, P1
Pertejo-Fernandez, A1
Gallego, A1
Martinez-Marin, V1
Zamora, P1
Espinosa, E1
Mendiola, M1
Feliu, J1
Redondo, A1
Veltsista, PD1
Oberacker, E1
Ademaj, A1
Corradini, S1
Eckert, F2
Flörcken, A1
Kaul, D1
Lindner, LH4
Issels, R1
Ott, OJ1
Pink, D1
Potkrajcic, V1
Reichardt, P3
Roohani, S1
Spalek, MJ1
Riesterer, O1
Zips, D2
Ghadjar, P2
Fetisov, TI1
Khazanova, SA1
Shtompel, PA1
Trapeznikova, ES1
Zinovieva, VY1
Marshall, VI1
Lovenger, AA1
Rogozhin, DV1
Anastasia, TA1
Bokhyan, BY1
Belitsky, GA1
Yakubovskaya, MG1
Kirsanov, KI1
Salah, S1
Abuhijla, F1
Ismail, T1
Yaser, S1
Sultan, I1
Halalsheh, H1
Shehadeh, A1
Abdelal, S1
Almousa, A1
Jaber, O1
Abu-Hijlih, R1
Hammer, KJ1
Copeland, VC1
Loggers, ET1
Pollack, SM1
Wagner, MJ1
Cranmer, LD1
Nakamura, Y1
Takemasa, A1
Kushima, Y1
Soda, S1
Ikeda, N1
Arai, R1
Chibana, K1
Nakazato, Y1
Yokose, T1
Shimizu, Y1
Niho, S1
Filleron, T1
Le Guellec, S1
Chevreau, C2
Cabarrou, B1
Lesluyes, T1
Lodin, S1
Massoubre, A1
Mounier, M1
Poublanc, M1
Chibon, F1
Valentin, T1
Imai, K1
Yamasaki, T1
Sakamoto, H1
Nakamura, K1
Mizowaki, T1
Ogawa, O1
Aoyama, T1
Xie, C1
Shen, Y1
Spałek, MJ1
Koseła-Paterczyk, H1
Borkowska, A1
Wągrodzki, M1
Szumera-Ciećkiewicz, A2
Czarnecka, AM1
Castaneda-Wysocka, P1
Kalinowska, I1
Poleszczuk, J1
Dąbrowska-Szewczyk, E1
Cieszanowski, A1
Rutkowski, P2
Hindi, N1
Tian, Z1
Yang, J1
Zhang, P1
Wang, X1
Zhang, F1
Li, P1
Teepen, JC1
van Leeuwen, FE1
Tissing, WJ1
van Dulmen-den Broeder, E1
van den Heuvel-Eibrink, MM1
van der Pal, HJ1
Loonen, JJ1
Bresters, D1
Versluys, B1
Neggers, SJCMM1
Jaspers, MWM1
Hauptmann, M1
van der Heiden-van der Loo, M1
Visser, O1
Kremer, LCM1
Ronckers, CM1
Issels, RD6
Verweij, J18
Wessalowski, R1
Wust, P1
Hohenberger, P2
Angele, M1
Salat, C2
Vujaskovic, Z1
Daugaard, S1
Mella, O1
Mansmann, U1
Dürr, HR1
Knösel, T1
Abdel-Rahman, S4
Schmidt, M1
Hiddemann, W2
Jauch, KW3
Belka, C1
García Del Muro, X2
Maurel, J3
Martínez Trufero, J1
Lavernia, J1
López Pousa, A1
de Las Peñas, R3
Cubedo, R2
Berros, JP1
Casado Herráez, A1
de Juan, A1
Martín Broto, J2
Fagerstedt, KW1
Salonen, T1
Zhao, F1
Kytölä, S1
Böhling, T1
Andersson, LC2
Jones, RL2
Arndt, CAS1
Charlson, J1
Lu, E1
Ryan, CW2
Spunt, SL2
Francotte, N1
De Salvo, GL1
Chi, YY1
Zanetti, I2
Hayes-Jordan, A1
Kao, SC1
Orbach, D1
Brennan, B1
Weiss, AR1
van Noesel, MM1
Million, L1
Parham, DM2
Kelsey, A1
Randall, RL1
McCarville, MB1
Hawkins, DS2
Wakamatsu, T1
Kakunaga, S1
Hamada, K1
Imura, Y1
Hori, Y1
Naka, N1
Kudawara, I1
Yoshikawa, H1
Ueda, T2
Chawla, SP2
Staddon, A1
Hendifar, A1
Messam, CA1
Patwardhan, R1
Kamel, YM1
Gani, C1
Kluba, T2
Mayer, F1
Kopp, HG2
Bamberg, M1
Müller, AC1
O'Donnell, PW1
Manivel, JC1
Cheng, EY1
Clohisy, DR1
Yoo, C1
Lee, J2
Park, KH1
Kim, TM1
Kim, YJ1
Lee, HJ2
Lee, KH1
Sio, TT1
Vu, CC1
Sohawon, S1
Van Houtte, P1
Thariat, J1
Novotny, PJ1
Miller, RC1
Bar-Sela, G1
Okuno, S1
Petersen, I1
Shives, T1
Mahoney, M1
Haddock, M1
Sim, F1
O'Connor, MI2
Markovic, SN1
Maples, W1
Judson, I3
Hartmann, JT1
Schöffski, P3
Kerst, JM1
Sufliarsky, J1
Whelan, J1
Krarup-Hansen, A2
Alcindor, T1
Marreaud, S1
Litière, S1
Hermans, C2
Fisher, C3
Hogendoorn, PC2
van der Graaf, WT1
Baumann, D1
Amann, K1
Schlatter, E1
Ciarimboli, G1
Müller, M1
Bakos, G1
Steinke, I1
Bunz, H1
Weyrich, P1
Artunc, F1
Mahmoud, O1
Dosch, A1
Kwon, D1
Pitcher, JD1
Conway, S1
Benedetto, P1
Fernandez, G1
Trent, J1
Temple, HT1
Wolfson, AH1
Roeder, F2
Lehner, B2
Schmitt, T3
Kasper, B4
Egerer, G4
Sedlaczek, O1
Grüllich, C1
Mechtersheimer, G2
Wuchter, P3
Hensley, FW1
Huber, PE1
Debus, J1
Bischof, M2
Kataoka, K1
Kimura, A1
Matsunobu, T1
Matsumine, A1
Araki, N2
Ibrahim, ZA1
Chan, WH1
Wong, SL2
Ong, EJ1
Narihan, MZ1
Brunetto, AL1
Castillo, LA1
Petrilli, AS1
Macedo, CD1
Boldrini, E1
Costa, C1
Almeida, MT1
Kirst, D1
Rodriguez-Galindo, C1
Pereira, WV1
Watanabe, FM1
Pizza, M1
Benites, E1
Morais, V1
Gadelha, A1
Nakasato, A1
Abujamra, AL1
Gregianin, LJ1
Liu, YP1
Jin, J1
Wang, WH1
Wang, SL1
Song, YW1
Fang, H1
Ren, H1
Liu, XF1
Yu, ZH1
Li, YX1
Schuler, M1
Davis, EJ1
Chugh, R3
Zhao, L1
Lucas, DR1
Biermann, JS2
Zalupski, MM3
Feng, M1
Jacobson, J2
Zyczynski, L1
Reinke, D1
Metko, G1
Baker, LH4
Schuetze, SM2
Fan, Z1
Patel, S2
Lewis, VO1
Guadagnolo, BA1
Lin, PP1
Ferrari, S2
Verderio, P3
De Paoli, A5
Comandone, A5
Sangalli, C1
De Sanctis, R1
Bottelli, S1
Libertini, M1
Mulder, RL3
Paulides, M3
Langer, T3
Kremer, LC3
van Dalen, EC3
Noujaim, J1
Constantinidou, A1
Messiou, C1
Thway, K1
Miah, A1
Benson, C1
Rizzato, MD1
Rastrelli, M1
Roma, A1
Maruzzo, M1
Basso, U1
Fiduccia, P1
Buzzaccarini, MS1
Rossi, CR1
Zagonel, V1
Mascarenhas, L1
Felgenhauer, JL1
Bond, MC1
Villaluna, D1
Femino, JD1
Laack, NN1
Ranganathan, S1
Meyer, J2
Womer, RB1
Gorlick, R2
Krailo, MD1
Marina, N2
Stubbe, F1
Agaimy, A1
Ott, O1
Lettmaier, S1
Vassos, N1
Croner, R1
Hohenberger, W1
Fietkau, R1
Semrau, S1
Wang, B1
Yu, X1
Xu, S1
Xu, M1
Moon, JY1
Baek, SW1
Ryu, H1
Choi, YS1
Song, IC1
Yun, HJ1
Jo, DY1
Kim, S1
Stoeckle, E1
Michot, A1
Rigal, L1
Babre, F1
Sargos, P1
Henriques de Figueiredo, B1
Brouste, V1
Italiano, A2
Toulmonde, M2
Le Loarer, F1
Kind, M2
Jevremovic, V1
Yousuf, A1
Hussain, Z1
Abboud, A1
Chedrawy, EG1
Saponara, M1
Frapolli, R1
Tortoreto, M1
Cominetti, D1
Provenzano, S2
Negri, T1
Dagrada, GP1
Colombo, C1
Vincenzi, B1
Badalamenti, G2
Zuco, V1
Renne, SL1
Collini, P1
Bello, E1
Pilotti, S1
D'Incalci, M1
Zaffaroni, N1
Dantonello, TM1
Int-Veen, C2
Harms, D1
Leuschner, I2
Schmidt, BF1
Herbst, M1
Juergens, H1
Scheel-Walter, HG1
Bielack, SS1
Dickerhoff, R1
Kirsch, S1
Brecht, I1
Schmelzle, R1
Greulich, M1
Gadner, H2
Greiner, J1
Marky, I2
Treuner, J3
Fra, J2
Martín, J5
Cruz, J1
Casado, A3
Poveda, A3
Martínez-Trufero, J2
Balañá, C2
Gómez, MA1
Gallego, O1
Rubio-Viqueira, B1
Rubió, J1
Andrés, R1
Sevilla, I1
de la Cruz, JJ1
Del Muro, XG1
Buesa, JM3
Granowetter, L1
Womer, R1
Devidas, M2
Krailo, M1
Bernstein, M1
Leavey, P1
Gebhardt, M2
Healey, J1
Shamberger, RC1
Goorin, A1
Miser, J2
Arndt, CA1
Sailer, S1
Marcus, K1
Perlman, E1
Dickman, P1
Grier, HE3
Benz, MR1
Czernin, J1
Allen-Auerbach, MS1
Tap, WD1
Dry, SM1
Elashoff, D1
Chow, K1
Evilevitch, V1
Eckardt, JJ2
Phelps, ME1
Weber, WA1
Eilber, FC4
Stahl, R1
Wang, T1
Santl, M1
Reiser, MF1
Ptaszyński, K1
Zakrzewska, K1
Tuziak, T1
Mrozkowiak, A1
Paulino, AC1
Pappo, A1
Ho, AD3
Sleijfer, S2
Ouali, M1
van Glabbeke, M5
Rodenhuis, S1
Le Cesne, A1
Jung, S1
Pavageau, AH1
Croué, A1
Reguerre, Y1
Rialland, X1
Rousselet, MC1
Bui-Nguyen, B1
Contreras Ibáñez, JA1
Navas García, N1
Díaz Gómez, L1
De Pas, T2
Rosati, G1
Spitaleri, G1
Boni, C1
Tucci, A1
Frustaci, S6
Scalamogna, R1
Radice, D1
Boselli, S1
Toffalorio, F1
Catania, C1
Noberasco, C1
Delmonte, A1
Vecchio, F1
de Braud, F2
Reed, D1
Altiok, S1
Lee, SH1
Chang, MH1
Baek, KK1
Han, B1
Lim, T1
Park, JO1
Mirza, T1
Ameerally, P1
Movva, S1
Verschraegen, C1
Dietrich, S1
Dimitrakopoulou-Strauss, A1
Strauss, LG1
Yang, Y2
Shi, Y1
Mercuri, M1
Mariani, L1
Valagussa, P1
Longhi, A1
Kushner, BH1
Modak, S1
Kramer, K1
Basu, EM1
Roberts, SS1
Cheung, NK1
Ferraro, A1
Majò, J1
Pizzamiglio, S1
Zhao, J1
Incorvaia, L1
Bronte, G1
Leto, G1
Fulfaro, F1
Maltese, G1
Serrone, L3
Nardoni, C2
Gelibter, A1
Felici, A1
Cognetti, F3
Felgenhauer, J2
Park, J1
Kreissman, S1
Thomson, B2
Douglas, J1
Rowley, SD1
Gooley, T1
Sanders, JE1
Pendergrass, TW1
van Oosterom, AT9
Mouridsen, HT6
Nielsen, OS3
Dombernowsky, P7
Krzemieniecki, K1
Svancarova, L1
Spooner, D3
Chen, LK1
Xu, GC2
Teng, XY1
Liang, Y1
Liu, JL1
Zhou, XM1
Huang, YH1
Wen, XP1
Hu, L1
Hardaway, CA1
Graham, BS1
Barnette, DJ1
Feldman, BD1
Wodowski, K1
Hill, DA1
Pappo, AS5
Shochat, SJ1
Kun, LE1
Wall, N1
Starkhammar, H1
O'Sullivan, B1
Bell, RS1
DeLaney, TF2
Spiro, IJ1
Suit, HD1
Gebhardt, MC2
Hornicek, FJ2
Mankin, HJ2
Rosenberg, AL1
Rosenthal, DI1
Miryousefi, F1
Ancukiewicz, M1
Harmon, DC1
Ogose, A1
Yazawa, Y1
Hotta, T1
Morita, T1
Mace, JR1
Keohan, ML1
Bernardy, H1
Junge, K1
Niebch, G1
Romeis, P1
Thoma, A1
Wagner, T2
Mueller, U1
Demetri, G1
Eilber, FR3
Eckardt, J4
Rosen, G5
Riedel, E2
Maki, RG2
Brennan, MF2
Singer, S2
Goto, T2
Kosaku, H1
Kobayashi, H1
Hozumi, T2
Kondo, T2
Chuman, H1
Grobmyer, SR1
Demetri, GD3
Mazumdar, M1
Fahn, W1
Worden, FP2
Taylor, JM2
Sondak, VK1
Leu, KM2
McGinn, CJ1
Stage, AC1
Pollock, RE2
Matin, SF1
Takahashi, S1
Suzuki, M1
Kume, H1
Matsumoto, S2
Okamoto, N1
Nishimatsu, H1
Tomita, K1
Kitamura, T1
Oppenheimer, O1
Athanasian, E1
Meyers, P1
Antonescu, CR1
Jenkins, J1
Rao, B1
Marcus, R1
Thomas, P1
Pratt, C1
Umeda, T5
Wada, T1
Ihara, K1
Isu, K1
Sugiura, H1
Yabe, H1
Tsugane, S1
Beppu, Y1
Virolainen, P1
Inoue, N1
Nagao, M1
Frassica, FJ1
Chao, EY1
Anderson, ME1
Raskin, KA1
Schafmayer, C1
Egberts, JH1
Kovács, G1
Tepel, J1
Bölke, E1
Ruf, L1
Budach, W2
Reinecke, P1
Röhrborn, A1
Pape, H2
Schwarz, A1
Schmitt, G2
Aul, C1
Meazza, C1
Carli, M1
Li, EX1
Zhang, YT1
Shang, JT1
Xu, Z1
Geng, Y1
Li, SM1
Shi, F1
Wu, YY1
Leyvraz, S4
Herrmann, R1
Guillou, L2
Honegger, HP1
Christinat, A1
Fey, MF1
Sessa, C2
Wernli, M1
Cerny, T3
Dietrich, D1
Pestalozzi, B1
Schlemmer, M1
Wendtner, CM1
Falk, M1
Licht, T1
Baumert, J1
Straka, C1
Hentrich, M1
Griffith, KA1
Thomas, DG1
Nakada, I1
Tascilar, M1
Loos, WJ1
Seynaeve, C1
Qiu, MZ1
Xu, F1
Wang, SS1
Luo, HY1
Wang, F1
Li, FH1
Sun, XF1
Lin, TY1
Huang, HQ1
Jiang, WQ1
Guan, ZZ1
Xu, RH1
Iagaru, A1
Masamed, R1
Menendez, LR1
Fedenko, A1
Conti, PS1
Boos, J1
Beske, F1
Hallmen, E1
Dantonello, T1
Montag, AG1
Hosenpud, JR1
Samuels, B1
Hayden, JB1
Hung, AY1
Mansoor, A1
Peabody, TD1
Mundt, AJ1
Undevia, S1
Takeuchi, S1
Akahoshi, Y1
Kasai, C1
Nishimoto, Y1
Stuart-Harris, R3
Harper, PG2
Kaye, SB2
Wiltshaw, E5
Stuart-Harris, RC1
Parsons, CA1
Mooney, CA1
Gowing, NF1
Burkert, H1
Utracka-Hutka, B1
Czownicki, Z1
Elias, AD3
Eilber, F2
Forscher, C3
Selch, M4
Fu, YS1
Schleicher, UM1
Adam, G1
Casser, HR1
Füzesi, L1
Ruymann, FB2
Vietti, T1
Gehan, E1
Wiener, E2
Wharam, M3
Newton, WA1
Maurer, H2
Bui, BN1
Chevallier, B2
Krakowski, I1
Peny, AM1
Thyss, A1
Maugard-Louboutin, C1
Cupissol, D1
Fargeot, P2
Bonichon, F1
Shinozaki, T1
Matsushita, M1
Kusawake, H1
Watanabe, H1
Arita, S1
Chigira, M1
Udagawa, E1
Kawaguchi, N1
Manabe, J1
Kuroda, H1
Shimoji, T1
Raney, B1
Ensign, LG1
Foreman, J1
Khan, F1
Newton, W1
Ortega, J1
Ragab, A1
Patel, SR6
Burgess, MA4
Plager, C3
Papadopoulos, NE1
Linke, KA1
Stuschke, M1
Hatakeyama, K1
Wakita, H1
Skubitz, KM1
Hamdan, H1
Thompson, RC1
Foladore, S1
Buonadonna, A2
Crivellari, D1
Carbone, A1
Sorio, R1
Morassut, S1
Monfardini, S1
Steward, W2
Mouridsen, H3
Edmonson, JH2
Ryan, LM1
Blum, RH2
Brooks, JS1
Shiraki, M1
Frytak, S1
Parkinson, DR1
Antman, K1
Crowley, J1
Balcerzak, SP2
Rivkin, SE1
Weiss, GR1
Elias, A3
Natale, RB1
Cooper, RM1
Barlogie, B1
Trump, DL1
González-Manzano, R1
Vieitez, JM1
Tangco, E1
Fernandez de Alava, E1
Herranz, P1
Garcia-Foncillas, J1
Hibi, S1
Naya, M1
Takaya, K1
Morimoto, M1
Kataoka, Y1
Todo, S1
Imashuku, S1
Kynaston, JA1
Malcolm, AJ1
Craft, AW1
Davies, SM1
Jones, PH1
King, DJ1
Mitchell, CD1
Oakhill, A1
Stiller, CA1
Bosse, D1
Starck, M1
Schildberg, FW1
Wilmanns, W2
Kampe, CE1
Lowenbraun, S1
Foster, J1
Steward, WP5
Somers, R9
Kerbrat, P2
Clavel, M4
Crowther, D2
Rouesse, J3
Tursz, T3
Tueni, E2
Gilard, V2
Malet-Martino, MC2
de Forni, M2
Niemeyer, U2
Ader, JC1
Martino, R2
Kitoh, M2
Tatezaki, S2
Satoh, T2
Legha, SS1
Nicaise, C1
Bramwell, VH3
Santoro, A9
Blackledge, G9
Onsrud, M2
Thomas, D7
Sylvester, R3
Weh, HJ2
Agarwal, K1
Zornig, C2
Schwarz, R2
Dietel, M2
Hossfeld, DK2
Dalley, D1
Bell, DR1
Levi, J1
Simes, RJ1
Schütte, J5
Kellner, R1
Seeber, S1
Azzarelli, A4
Casali, P3
Fissi, S1
Montalto, F1
Budd, GT1
Metch, B1
Weiss, SA1
Weick, JK1
Fabian, C1
Stephens, RL1
Harstrick, A2
Bokemeyer, C2
Schmoll, HJ2
Köhne-Wömpner, CH2
Knipp, H1
Anagnou, J1
Wipperman, B1
Neumann, S1
Poliwoda, H2
Pastorino, U2
Bertulli, R1
Zucchinelli, P2
Devizzi, L2
Toma, S4
Palumbo, R3
Canavese, G2
Albanese, E1
Cantoni, E1
Barisone, A1
Reggiardo, G1
Rosso, R2
Santi, L2
Edmonson, J1
Ryan, L3
Pelletier, L1
Olivier, JP1
Facchini, T1
Vo Van, ML1
Vantongelen, K1
Bui, NB1
Stöckle, E1
Kantor, G1
Thomas, L1
Wexler, LH1
Tsokos, M1
Avila, N1
Steinberg, SM1
Weaver-McClure, L1
Jarosinski, P1
Hijazi, YM1
Balis, FM1
Horowitz, ME1
Boddy, AV1
English, M1
Pearson, AD1
Idle, JR1
Skinner, R1
Erkisi, M1
Erkurt, E1
Ozbarlas, S1
Burgut, R1
Doran, F1
Seyrek, E1
Lokiec, F1
Santoni, J1
Weill, S1
Tubiana-Hulin, M1
Baranzelli, MC1
Pichon, F1
Gourmel, B1
N'Guyen, M1
Deligny, N1
Demaille, MC1
Saboorian, MH1
Ashfaq, R1
Vandersteenhoven, JJ1
Schneider, NR1
Vadhan-Raj, S1
Papadopolous, N1
Hays, C1
Bellmunt, J2
Eres, N1
Ribas, A1
Casado, S1
Albanell, J1
Baselga, J1
Therasse, P1
Saeter, G2
Alvegård, TA2
Monge, OR1
Strander, H2
Turesson, I1
Klepp, R1
Söderberg, M1
Wist, E1
Raabe, N1
Erlanson, M1
Solheim, OP1
Hannisdal, E1
Palmeri, S1
Antimi, M1
Gatti, C2
Raffo, P1
Villani, G1
Walter, AW1
Shearer, PD1
Greenwald, CA1
Rao, BN2
Bowman, LC1
Furman, WL1
Gajjar, A1
Jenkins, JJ1
Pratt, CB2
Theis, JG1
Chan, HS1
Greenberg, ML1
Malkin, D1
Karaskov, V1
Moncica, I1
Koren, G1
Doyle, J1
Lévy, E1
Thirion, P1
Piedbois, P1
Kito, M1
Antón, A1
García del Muro, J1
Arranz, F1
Valentí, V1
Escudero, P1
Menéndez, D1
Bacchi, M1
Lissoni, A1
Bressoud, A1
Hermann, R1
Orlando, L1
Nolè, F1
Munzone, E1
Zampino, MG1
Fazio, N1
Aapro, MS1
Goldhirsch, A1
Leone, L1
Oliva, C1
Monteleone, M1
Colussi, AM1
Dal Canton, O1
Bergnolo, P1
Boglione, A1
Bumma, C1
Yalçin, S1
Fernberg, JO1
Wiklund, T1
Monge, O1
Hall, KS1
Marina, NM1
Cain, AM1
Poquette, CA1
Greenwald, C1
Meyer, WH1
Hawkins, D1
Radich, J1
Shetty, AK1
Yu, LC1
Gardner, RV1
Warrier, RP1
Sawyer, M1
Bramwell, V3
Brodowicz, T2
Köstler, WJ2
Wiltschke, C1
Zielinski, CC2
Huuhtanen, RL1
Wiklund, TA2
Blomqvist, CP2
Böhling, TO1
Virolainen, MJ1
Tribukait, B1
Dinçol, D1
Samur, M1
Pamir, A1
Sencan, O1
Akbulut, H1
Yalçin, B1
Onur, H1
Demirkazik, A1
Senler, FC1
Içli, F1
Kerbusch, T1
Huitema, AD1
Ouwerkerk, J1
Keizer, HJ1
Mathôt, RA1
Schellens, JH1
Beijnen, JH1
Pápai, Z1
Bodoky, G1
Szántó, J1
Poller, I1
Rahóty, P1
Eckhardt, S1
Láng, I1
Szendroi, M1
Kennedy, JG1
Eustace, S1
Caulfield, R1
Fennelly, DJ1
Hurson, B1
O'Rourke, KS1
Späth-Schwalbe, E1
Genvresse, I1
Koschuth, A1
Dietzmann, A1
Grunewald, R1
Possinger, K1
Gwyther, SJ1
Judson, IR1
Meric, F1
Milas, M1
Hunt, KK2
Hess, KR1
Pisters, PW2
Hildebrandt, G1
Papadopolous, NE1
Feig, BW2
Bouhour, D1
Ray-Coquard, I1
Dumontet, C2
Philip, T2
Biron, P2
Lejeune, FJ1
Pujol, N1
Liénard, D1
Mosimann, F1
Raffoul, W1
Genton, A1
Landry, M1
Chassot, PG1
Chiolero, R1
Bischof-Delaloye, A1
Mirimanoff, RO1
Bejkos, D1
Leyvraz, PF1
Nelson, SD2
Gherlinzoni, F1
Bonetti, M1
Olmi, P1
Pignatti, G1
Barbieri, E1
Apice, G1
Zmerly, H1
Serraino, D1
Schneeweiss, A1
Hensel, M1
Goerner, R1
Khbeis, T1
Hohaus, S1
Solomayer, E1
Haas, R1
Grischke, EM1
Bastert, G1
Thall, PF1
Cheng, SC1
Zeuli, M2
Gamucci, T1
Nardi, M1
Mochizuki, K1
Katayama, K1
Kikuchi, F1
Saito, I1
Homori, M1
Dorey, F1
Lovett, BD1
Lo Nigro, L1
Rappaport, EF1
Blair, IA1
Osheroff, N1
Zheng, N1
Megonigal, MD1
Williams, WR1
Nowell, PC1
Felix, CA1
Papaldo, P1
Pacetti, U1
Attems, Y1
Hejna, M1
Tomek, S1
Amann, G1
Fiebiger, WC1
Wiltschke, CH1
Krainer, M1
Cormier, JN1
Herzog, CE1
Ballo, MT1
Raney, RB3
Zagars, GK1
Anderson, JR1
Barr, FG1
Donaldson, SS2
Qualman, SJ1
Wiener, ES1
Maurer, HM2
Crist, WM2
Breitfeld, PP1
Lyden, E1
Teot, LA1
Lobe, T1
Petersen, IA1
Shives, TC1
Mahoney, MR1
Rock, MG1
Haddock, MG1
Sim, FH1
Maples, WJ1
Gunderson, LL1
Foo, ML1
Pritchard, DJ1
Buckner, JC1
Stafford, SL1
van Oosterom, A2
Buesa, J1
Van Glabekke, M1
Bouffet, E1
Meckenstock, R1
Chauvin, F1
Philip, I1
Brunat-Mentigny, M1
Antman, KH5
Crasnier, F1
Chouini-Lalanne, N1
Virolainen, M1
Elomaa, I1
Sogno, G1
Venturino, A1
Bignami, P1
Bonadonna, G1
Weiss, RB1
Pinkerton, CR1
Stornes, I1
Mejlholm, I1
Jakobsen, A1
Greifenberg, B1
Soedirman, J1
Shaw, PJ1
Eden, T1
Coialbu, T1
Biassoni, L1
Folco, U1
Giacchero, A1
Prenninger, SW1
Nagele, A1
Boehm, E1
Sauer, H1
Denecke, H1
Berger, H1
Peter, K1
Zaidi, SH1
Iqbal, Z1
Mallick, JA1
Küpfer, A1
Zeugin, T1
Brunner, KW1
Zügel, M1
Wingberg, D1
Stewart, W2
Dirix, LY2
Budach, V1
Scheulen, M1
Czeglarski, G1
Sherman, D1
Willemse, PH1
de Vries, EG1
Sulkes, A1
Collins, J1
Aisner, J1
Boven, E1
Calame, JJ1
Molthoff, CF1
Pinedo, HM3
Keim, M1
Troxler, M1
Quirt, I1
Warr, D1
Verma, S1
Young, V1
Knowling, M1
Eisenhauer, E1
Meanwell, CA1
Blake, AE1
Kelly, KA1
Honigsberger, L1
Westbury, G1
Harmer, C1
McKinna, A1
Klein, HO1
Dias Wickramanayake, P1
Coerper, C1
Christian, E1
Cantwell, BM1
Carmichael, J1
Ghani, S1
Harris, AL1
Mansi, JL1
MacMillan, S1
King, M1
Zamboglou, N1
Fürst, G1
Bannach, B1
Molls, M1
Cavalli, F1
Verwey, J1
von Oosterom, A1
Hartlapp, JH2
Münch, HJ2
Illiger, HJ2
Wolter, H2
Jensen, JC2
de Kraker, J1
Voûte, PA1
Magrath, I1
Sandlund, J1
Raynor, A1
Rosenberg, S1
Arasi, V1
Brade, WP1
Herdrich, K1
Varini, M1
Montella, D1
Rosenbaum, C1
Schwen, M1

Clinical Trials (26)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma[NCT03809637]Phase 237 participants (Actual)Interventional2017-01-10Active, not recruiting
Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials: A Study of Participation Patterns Among Those Affected by the Disorder[NCT06029465]500 participants (Anticipated)Observational2024-10-31Not yet recruiting
Pegylated-liposome Doxorubicin Combined With Ifosfamide As First-line Treatment for Patients With Advanced or Metastatic Soft Tissue Sarcoma[NCT03268772]Phase 240 participants (Actual)Interventional2015-04-01Active, not recruiting
Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Soft Tissue Sarcoma[NCT04307277]Phase 3600 participants (Anticipated)Interventional2020-10-09Recruiting
Randomized Study Comparing Neoadjuvant Chemotherapy Etoposide + Ifosfamide + Adriamycin (EIA) Combined With Regional Hyperthermia (RHT) Versus Neoadjuvant Chemotherapy Alone in the Treatment of High-Risk Soft Tissue Sarcomas in Adults[NCT00003052]Phase 3340 participants (Anticipated)Interventional1997-07-31Completed
Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age[NCT00346164]Phase 3588 participants (Actual)Interventional2007-02-05Completed
An Open-label, Dose Ranging Study to Assess the Safety, Efficacy, and Pharmacokinetics of an Oral Thrombopoietin Receptor Agonist (Eltrombopag) Administered to Subjects Receiving Adriamycin and Ifosfamide (AI) Regimen[NCT00358540]Phase 118 participants (Actual)Interventional2006-06-01Completed
An Evaluation of PET/CT Imaging as a Predictor of Disease Free Survival Following Neo-Adjuvant Chemotherapy for Soft Tissue Sarcoma[NCT00346125]70 participants (Actual)Interventional2006-04-10Completed
A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas[NCT01830153]Phase 241 participants (Actual)Interventional2010-04-30Completed
A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy[NCT02711007]Phase 2/Phase 337 participants (Actual)Interventional2016-03-31Completed
Randomised Trial Of Single Agent Doxorubicin Versus Doxorubicin Plus Ifosfamide In The First Line Treatment Of Advanced Or Metastatic Soft Tissue Sarcoma[NCT00061984]Phase 3455 participants (Actual)Interventional2003-04-30Completed
Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)[NCT02793050]510 participants (Actual)Observational2016-06-15Completed
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.[NCT03375437]376 participants (Actual)Interventional2018-02-15Active, not recruiting
A Phase II Study Evaluating Neo-/Adjuvant EIA Chemotherapy, Surgical Resection and Radiotherapy in High-risk Soft Tissue Sarcoma[NCT01382030]Phase 250 participants (Actual)Interventional2005-06-30Completed
Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy[NCT01710176]Phase 3550 participants (Actual)Interventional2011-06-01Active, not recruiting
A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults[NCT00876031]Phase 3195 participants (Actual)Interventional2009-07-01Completed
The Use of Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Treatment of High-grade Extremity Soft Tissue and Non-metastatic Sarcomas[NCT02812654]Phase 270 participants (Anticipated)Interventional2015-03-31Recruiting
Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405]97 participants (Actual)Interventional2016-10-31Terminated (stopped due to Withdrawal of analysis study Partner.)
First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas[NCT01469975]Phase 120 participants (Actual)Interventional2011-12-31Terminated (stopped due to Too slow accrual.)
A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression[NCT01391962]Phase 234 participants (Actual)Interventional2011-07-18Active, not recruiting
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft Tissue Sarcoma After Pre-treatment Failure: an Open-label, Multicenter Phase II Study[NCT01136499]Phase 253 participants (Actual)Interventional2010-01-31Completed
A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma[NCT01755195]Phase 255 participants (Actual)Interventional2013-01-15Active, not recruiting
Determination of Tumor Response Rate by RECIST and FDG-PET Criteria to Dacarbazine in Metastatic Soft Tissue and Bone Sarcoma[NCT00802880]Phase 280 participants (Actual)Interventional2009-03-31Completed
Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus[NCT03342300]Phase 2/Phase 30 participants (Actual)Interventional2017-11-06Withdrawn (stopped due to No participants enrolled)
A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595]Phase 20 participants (Actual)Interventional2009-02-28Withdrawn (stopped due to No patients accrued since study opened)
A Phase II Study on Preoperative Administration of Gleevec in Patients With Initially Non-Resectable Gastrointestinal Stromal Tumor[NCT00290485]Phase 250 participants Interventional2005-08-31Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Complete or Partial Response Rate

Tumor response by imaging. Complete Response (CR): Complete disappearance of the tumor. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Overall Response (OR)=CR+PR. (NCT00346164)
Timeframe: 13 weeks

Interventionpercentage of patients (Number)
Arm D33.1

Event Free Survival Probability Disease Extent

Probability of no relapse, secondary malignancy or death after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years

InterventionProbability (Number)
Non-metastatic0.7758
Metastatic0.1960

Event Free Survival Probability Histologic Grade

Probability of no relapse, secondary malignancy or death after 5 years since enrollment (NCT00346164)
Timeframe: 5 years

InterventionProbability (Number)
Histologic Grade 10.9636
Histologic Grade 20.8505
Histologic Grade 30.6136

Incidence of Distant Metastasis

Percent of patients who had distant metastasis. (NCT00346164)
Timeframe: Up to 10 years

InterventionPercentage of participants (Number)
Non-metastatic10.59
Metastatic60.87
Histologic Grade 10.00
Histologic Grade 25.06
Histologic Grade 323.38

Overall Survival Probability Disease Extent

Probability of survival after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years

InterventionProbability (Number)
Non-metastatic0.8752
Metastatic0.3153

Overall Survival Probability Extent of Resection of the Primary Tumor

Probability of survival after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years

InterventionProbability (Number)
Less Than Total Resection0.5975
Negative Margins0.9353
Positive Margins0.7764

Percent Tumor Necrosis

Percent tumor necrosis by pathology review. (NCT00346164)
Timeframe: 13 weeks

Interventionpercentage of tumor necrosis (Mean)
Arm D59.4

Probability for Event Free Survival.

Probability of no relapse, secondary malignancy or death after 5 years since enrollment. (NCT00346164)
Timeframe: 5 years

InterventionProbability of EFS at 5 years (Number)
Arm A: No Adjuvant Treatment0.8984
Arm B: Low Risk; Adjuvant Radiotherapy0.7647
Arm C: Intermediate & High Risk; Adjuvant Chemoradiotherapy0.6079
Arm D: Intermediate & High Risk; Neoadjuvant Chemoradiotherapy0.4873

Toxicity Rate

Percentage of Arm D patients experiencing grade 4+ adverse events. (NCT00346164)
Timeframe: 13 weeks

Interventionpercentage of participants (Number)
Arm D3.06

Degree of Agreement in Histologic Grade Between Pediatric Oncology Group (POG) and Fédération Nationale Des Centres de Lutte Contre le Cancer (FNCLCC) Pathologic Grading Systems

POG and FNCLCC grades were determined by pathologists based on published standards. A higher grade is associated with a more severe disease. (NCT00346164)
Timeframe: At diagnosis

,,
InterventionParticipants (Count of Participants)
Histologic grade 1 by POGHistologic grade 2 by POGHistologic grade 3 by POG
Histologic Grade 1 by FNCLCC46249
Histologic Grade 2 by FNCLCC869145
Histologic Grade 3 by FNCLCC10240

Degree of Agreement in Histologic Grade Determined by the Enrolling Institution Versus by Central Pathology Reviewers

Histologic grades were determined by the central pathology reviewers and institutional pathologists based on published standards. A higher grade is associated with a more severe disease. (NCT00346164)
Timeframe: At Diagnosis

,,
InterventionParticipants (Number)
Histologic grade 1 by central pathology reviewersHistologic grade 2 by central pathology reviewersHistologic grade 3 by central pathology reviewers
Histologic Grade 1 by Enrolling Institution3843
Histologic Grade 2 by Enrolling Institution55610
Histologic Grade 3 by Enrolling Institution19268

Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)

Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.

InterventionParticipants (Count of Participants)
Cabozantinib53

Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas

Objective response was assessed by the Response Evaluation Criteria in Solid Tumors RECIST) v1.1. Complete Response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. (NCT01755195)
Timeframe: Date treatment consent signed to date off study, approximately 86 months and 3 days.

Interventionpercentage of particpants (Number)
Cabozantinib11.1

Percentage of Participants With 6 Month Progression Free Survival (PFS)

Progression in participants with soft tissue sarcomas treated with cabozantinib was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study. The appearance of one or more new lesions is also considered progressions. (NCT01755195)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Cabozantinib49.3

Mean Change From Baseline in Levels of Circulating Hepatocyte Growth Factor (HGF)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of HGF. HGF protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionpg/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day 1
Cabozantinib-51.3344.8

Mean Change From Baseline in Levels of Circulating Soluble Mesenchymal Epithelial Transition Factor (sMET)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble MET (sMET). sMET protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionng/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day1
Cabozantinib-6.116.4

Mean Change From Baseline in Levels of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (sVEGFR-2)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of soluble VEGFR2 (sVEGFR-2). sVEGFR-2 protein content (in nanograms; ng) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome.. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionng/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day 1
Cabozantinib-1.0-10.9

Mean Change From Baseline in Levels of Circulating Vascular Endothelial Growth Factor A (VEGF-A)

Blood samples were collected before treatment on the first day of cycles 1 and 2 to determine circulating levels of VEGF-A. VEGF-A protein content (in picograms; pg) in blood plasma (in milliliters; mL) was measured for each sample with a two-site immunoassay and the difference from before to after treatment for each patient was reported. A change in this biomarker from the baseline value has not been linked to clinical outcomes; that is, it is neither a good or a bad outcome. (NCT01755195)
Timeframe: Baseline to Cycle 1 Day 1 and baseline to Cycle 2 Day 1

Interventionpg/mL (Mean)
Baseline to Cycle 1 Day 1Baseline to Cycle 2 Day 1
Cabozantinib5.632.5

Overall Survival

(NCT00802880)
Timeframe: Until completion of follow-up or patient death (estimated to be 1 year)

Interventionmonths (Median)
Dacarbazine8.09

Rate of Nausea/Emesis (Any Grade)

Approximately 18 weeks (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)

Interventionpercentage of participants (Number)
Dacarbazine22.5

Rate of Neutropenia (Grade 3/4)

"Grade 3 neutropenia = absolute neutrophil count of <1000 - 500/mm^3~Grade 4 neutropenia = absolute neutrophil count of <500/mm^3" (NCT00802880)
Timeframe: Completion of 6 cycles of treatment (18 weeks)

Interventionpercentage of participants (Number)
Dacarbazine7.5

Time to Progression (TTP)

-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Until completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Dacarbazine2.07

Best Anatomical Tumor Response

"Complete response (CR): disappearance of all target lesions, disappearance of all non-target lesions, normalization of tumor level marker~Partial response (PR): at least 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the upper limits of normal~Stable disease (SD): neither sufficient shrinkage in target lesions to qualify for PR nor sufficient increase to qualify for progressive disease taking as references the smallest sum LD since the treatment started, persistence of one or more non-target lesion and/or maintenance of tumor marker level above the normal limits of normal~Progressive disease (PD): at least 20% increase in the sum of the LD of target lesions and/or appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions" (NCT00802880)
Timeframe: After completion of 3 cycles

Interventionparticipants (Number)
Complete responsePartial responseStable diseaseProgressive disease
Dacarbazine022230

Comparison of the SUV at up to 3 Tumor Sites

(NCT00802880)
Timeframe: Baseline and after every three cycles of treatment (up to 1 year)

Interventionstandard uptake value (Mean)
BaselineEnd of cycle 3End of cycle 6End of cycle 9End of cycle 12
Dacarbazine7.427.577.76.897.48

Correlate Overall Survival With Best Anatomic Response

(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial responseStable diseaseProgressive disease
Dacarbazine18.1614.777.96

Correlate Overall Survival With Best Metabolic Response

(NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial metabolic responseStable metabolic diseaseProgressive metabolic disease
Dacarbazine18.1618.598.75

Correlate the Time to Progression With Best Anatomic Response

-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial responseStable diseaseProgressive disease
DacarbazineNA4.141.97

Correlate the Tumor Metabolic Response Rate With the Tumor Anatomic Response Rate

(NCT00802880)
Timeframe: After completion of 3 cycles

,,,
Interventionparticipants (Number)
PRSDPDTotal
Partial Metabolic Response1214
Progressive Metabolic Disease182433
Stable Metabolic Disease010212
Total2202749

Correlate Time to Progression With Best Metabolic Response

-Progression - At least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. (NCT00802880)
Timeframe: Completion of follow-up (estimated to be 1 year)

Interventionmonths (Median)
Partial metabolic responseStable metabolic diseaseProgressive metabolic disease
Dacarbazine3.955.302.07

Overall Disease Control Rate

(NCT00802880)
Timeframe: 12 months

Interventionparticipants (Number)
Complete responsePartial responseStable diseaseProgressive disease
Dacarbazine0051

Overall Tumor Metabolic Response

"Complete metabolic response (CMR)-complete resolution of all metabolically active target and non-target lesions, and no interval development of new lesions.~Partial metabolic response (PMR)~Target lesions: 20% or greater decrease in maximum SUV from baseline. No unequivocal metabolic progression of non-target disease, and no unequivocal new lesions.~Non-target lesions: decrease in total number of non-target lesions, without complete resolution of metabolically active disease, or unequivocal decrease in degree of FDG activity within >50% of the lesions. No unequivocal new lesions.~Stable metabolic disease (SMD): does not qualify for CMR, PMR, or PMD.~Progressive metabolic disease (PMD):~Unequivocal development of one more new metabolically active lesions~Target lesion: 20% or greater increase in maximum SUV from baseline.~Non-target lesions: unequivocal increase in FDG activity" (NCT00802880)
Timeframe: After completion of 3 cycles

Interventionparticipants (Number)
CMRPMRSMDPMD
Dacarbazine041334

Reviews

49 reviews available for ifosfamide and Soft Tissue Neoplasms

ArticleYear
The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives.
    Current treatment options in oncology, 2021, 10-23, Volume: 22, Issue:12

    Topics: Anthracyclines; Antineoplastic Agents; Chemotherapy, Adjuvant; Epigenomics; Gene Expression Regulati

2021
Hyperthermia in the treatment of high-risk soft tissue sarcomas: a systematic review.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2023, Volume: 40, Issue:1

    Topics: Combined Modality Therapy; Humans; Hyperthermia, Induced; Ifosfamide; Sarcoma; Soft Tissue Neoplasms

2023
What is the standard indication of adjuvant or neoadjuvant chemotherapy in localized soft-tissue sarcoma?
    Current opinion in oncology, 2021, 07-01, Volume: 33, Issue:4

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri

2021
Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned.
    Cancer treatment reviews, 2018, Volume: 68

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dactinomycin; Europe; Human

2018
Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy.
    Current treatment options in oncology, 2018, 10-25, Volume: 19, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D

2018
[Multimodal treatment of sarcomas: standards and new aspects in pharmacological and radio-oncological treatment].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2019, Volume: 90, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; H

2019
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    The Cochrane database of systematic reviews, 2015, Sep-30, Issue:9

    Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid

2015
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid

2010
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid

2010
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid

2010
Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Tr
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epid

2010
Palifosfamide, a bifunctional alkylator for the treatment of sarcomas.
    IDrugs : the investigational drugs journal, 2010, Volume: 13, Issue:1

    Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Drug Evaluation, Preclinic

2010
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    The Cochrane database of systematic reviews, 2010, Feb-17, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamide; Sarc

2010
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
    Bulletin du cancer, 2010, Volume: 97, Issue:6

    Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Hu

2010
Metastatic soft tissue sarcoma chemotherapy: an opportunity for personalized medicine.
    Cancer control : journal of the Moffitt Cancer Center, 2011, Volume: 18, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Doxorubici

2011
Leiomyosarcoma of the tongue with multiple metastases: a case report and review of literature.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2012, Volume: 70, Issue:7

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy

2012
Systemic management strategies for metastatic soft tissue sarcoma.
    Drugs, 2011, Nov-12, Volume: 71, Issue:16

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dioxoles; Doxo

2011
The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group.
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; C

2012
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature.
    Cancer, 2013, Feb-01, Volume: 119, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carboplati

2013
Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients.
    The Cochrane database of systematic reviews, 2012, Dec-12, Volume: 12

    Topics: Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Humans; Ifosfamid

2012
A chemosensitive pediatric extraosseous osteosarcoma: case report and review of the literature.
    Journal of pediatric hematology/oncology, 2003, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Doxorubicin; Female; Human

2003
[Soft tissue sarcoma: postoperative chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos

2004
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin;

2004
Emerging treatments for soft tissue sarcoma of adults.
    Expert opinion on emerging drugs, 2004, Volume: 9, Issue:2

    Topics: Adult; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Ther

2004
Bilateral metastatic renal synovial sarcoma.
    Urology, 2005, Volume: 65, Issue:2

    Topics: Amputation, Surgical; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Female; Forearm;

2005
Malignant ectomesenchymoma in the wrist of a child: case report and review of the literature.
    International journal of surgical pathology, 2005, Volume: 13, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin

2005
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
    The oncologist, 2007, Volume: 12, Issue:11

    Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Doxorubicin; Drug Thera

2007
Ifosfamide: European perspective.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat

1982
Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.
    Hematology/oncology clinics of North America, 1995, Volume: 9, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini

1995
Preoperative therapy for soft tissue sarcoma.
    Hematology/oncology clinics of North America, 1995, Volume: 9, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials a

1995
[Chemotherapy for soft tissue sarcoma--current concepts and review].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Humans; Ifosfam

1993
Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Acetylcysteine; Bone Neoplasms; Fluid Therapy; Humans; Ifosfamide; Mesna; Randomized Controlled Tria

1993
Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase

1993
High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C

1996
[Locally developed sarcoma of the thoracic wall].
    Bulletin du cancer, 1996, Volume: 83, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Back; Chemotherapy, Adjuvant; Combined Modality Ther

1996
[Adjuvant chemotherapy of soft tissue sarcoma].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 1997, Volume: 1, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Fo

1997
Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
    Acta orthopaedica Scandinavica. Supplementum, 1999, Volume: 285

    Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic;

1999
The treatment of distant metastases in soft tissue sarcoma.
    Seminars in radiation oncology, 1999, Volume: 9, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality

1999
Extraskeletal Ewing's sarcoma: a case report and review of the literature.
    Spine, 2000, Aug-01, Volume: 25, Issue:15

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cervical Vertebrae; Combined Modality Therapy

2000
Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma.
    Cancer, 2001, Sep-15, Volume: 92, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Child, Preschool; Combined Mo

2001
Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.
    Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Clin

2001
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma;

1992
The clinical management of soft tissue sarcomas.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Humans; Ifosfam

1992
Chemotherapy of advanced sarcomas of bone and soft tissue.
    Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Dacarbazin

1992
Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Ifosfamide; Sarcoma

1992
Megatherapy for soft tissue sarcomas. EBMT experience.
    Bone marrow transplantation, 1991, Volume: 7 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Dacti

1991
Ifosfamide in paediatric oncology: tried but not tested?
    Lancet (London, England), 1990, Apr-28, Volume: 335, Issue:8696

    Topics: Child; Cyclophosphamide; Evaluation Studies as Topic; Humans; Ifosfamide; Neoplasms; Prognosis; Sarc

1990
The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review.
    Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sarcoma,

1990
The role of ifosfamide in the treatment of sarcomas.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sa

1989
Chemotherapy of advanced soft-tissue sarcomas.
    Seminars in surgical oncology, 1988, Volume: 4, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Dru

1988
The treatment of soft tissue sarcomas with focus on chemotherapy: a review.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1986, Volume: 5, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy;

1986
Ifosfamide--pharmacology, safety and therapeutic potential.
    Cancer treatment reviews, 1985, Volume: 12, Issue:1

    Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu

1985

Trials

104 trials available for ifosfamide and Soft Tissue Neoplasms

ArticleYear
Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial.
    ESMO open, 2021, Volume: 6, Issue:5

    Topics: Cisplatin; Humans; Ifosfamide; Pemetrexed; Sarcoma; Soft Tissue Neoplasms

2021
Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
    Cancer, 2022, Jan-01, Volume: 128, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Humans; Ifosfamide; N

2022
Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults.
    Pediatric blood & cancer, 2022, Volume: 69, Issue:9

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Doxorubicin; Humans

2022
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.
    British journal of cancer, 2022, Volume: 127, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Febrile Neutr

2022
Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Treating Advanced or Metastatic Soft-tissue Sarcoma: A Prospective, Single-arm Phase II Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 12-15, Volume: 28, Issue:24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Neoplasms, Second P

2022
Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.
    BMC cancer, 2020, Jul-31, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Doxorubicin; Hum

2020
Combined Preoperative Hypofractionated Radiotherapy With Doxorubicin-Ifosfamide Chemotherapy in Marginally Resectable Soft Tissue Sarcomas: Results of a Phase 2 Clinical Trial.
    International journal of radiation oncology, biology, physics, 2021, 07-15, Volume: 110, Issue:4

    Topics: Adult; Aged; Dose Fractionation, Radiation; Doxorubicin; Female; Humans; Ifosfamide; Male; Middle Ag

2021
Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
    JAMA oncology, 2018, Apr-01, Volume: 4, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

2018
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
    Investigational new drugs, 2018, Volume: 36, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Fema

2018
Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 112

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined

2019
Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
    BMC cancer, 2013, Mar-16, Volume: 13

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Dose-

2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Bone Neoplasms; E

2013
Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively.
    American journal of clinical oncology, 2016, Volume: 39, Issue:2

    Topics: Administration, Inhalation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2016
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free

2014
Excellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial.
    BMC cancer, 2014, May-20, Volume: 14

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe

2014
A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; D

2014
Carboplatin in the treatment of Ewing sarcoma: Results of the first Brazilian collaborative study group for Ewing sarcoma family tumors-EWING1.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:10

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brazil; Carboplatin; Chi

2015
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine;

2015
Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Español de Investigación en Sarcomas Randomized Clinical Trial: Three Versus Fiv
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

2015
Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Mar-20, Volume: 27, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined

2009
Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-10, Volume: 27, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dise

2009
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, May-20, Volume: 27, Issue:15

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool;

2009
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2009, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com

2009
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2009, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com

2009
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2009, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com

2009
Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS).
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2009, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Com

2009
Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.
    Chemotherapy, 2011, Volume: 57, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedu

2011
A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma.
    BMC cancer, 2011, Dec-07, Volume: 11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali

2011
Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Mar-10, Volume: 30, Issue:8

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas

2012
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:18

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Disease Progression; Dose-Response Relationship, Dru

2002
[Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
    Ai zheng = Aizheng = Chinese journal of cancer, 2002, Volume: 21, Issue:8

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Fem

2002
Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
    International journal of radiation oncology, biology, physics, 2003, Jul-15, Volume: 56, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Dox

2003
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-01, Volume: 9, Issue:16 Pt 1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Cross-Over Studies; Female; Hu

2003
Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Cancer, 2004, Apr-01, Volume: 100, Issue:7

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined

2004
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe

2004
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-01, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Ant

2005
Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:2

    Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bo

2005
Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-20, Volume: 23, Issue:18

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Doxoru

2005
Alternating sequential chemotherapy with high-dose ifosfamide and doxorubicin/cyclophosphamide for adult non-small round cell soft tissue sarcomas.
    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2005, Volume: 10, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female;

2005
Full-dose ifosfamide can be safely administered to outpatients.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:2

    Topics: Adolescent; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool

2008
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies.
    British journal of cancer, 2006, Nov-20, Volume: 95, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship,

2006
Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
    Oncology, 2006, Volume: 71, Issue:1-2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etopo

2006
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
    Cancer, 2007, Jun-01, Volume: 109, Issue:11

    Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Breath Tests; Cytochrome P-450 CYP3A; Cytochrom

2007
Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphami

2008
Histologic response of dose-intense chemotherapy with preoperative hypofractionated radiotherapy for patients with high-risk soft tissue sarcomas.
    Cancer, 2008, Volume: 112, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose Fractio

2008
Ifosfamide: European perspective.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat

1982
[Preliminary evaluation of the effectiveness of holoxan in the treatment of malignant soft tissue and bone neoplasms].
    Nowotwory, 1981, Volume: 31, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Clinical Trials a

1981
Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
    Journal of pediatric hematology/oncology, 1995, Volume: 17, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Dact

1995
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:10

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Double-Blind Met

1995
[Ifosfamide-induced hemorrhagic cystitis and its prevention by mesna].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin;

1995
Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
    The American journal of pediatric hematology/oncology, 1994, Volume: 16, Issue:4

    Topics: Acute Kidney Injury; Adolescent; Adult; Chemotherapy, Adjuvant; Child; Child, Preschool; Creatinine;

1994
[Value of neoadjuvant radiochemotherapy in undifferentiated soft tissue sarcomas].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1994, Volume: 170, Issue:8

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemothe

1994
Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
    Cancer, 1993, Nov-15, Volume: 72, Issue:10

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols;

1993
Epirubicin and ifosfamide in advanced soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Feasibility Stu

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo

1993
Phase II evaluation of doxorubicin, ifosfamide, and dacarbazine plus amphotericin B in the treatment of metastatic soft tissue sarcomas. A pilot study.
    American journal of clinical oncology, 1993, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Amphotericin B; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxo

1993
Synovial sarcoma. A study of intensive chemotherapy in 14 patients with localized disease.
    Cancer, 1993, Oct-01, Volume: 72, Issue:7

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin

1993
Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Chi-Square Distribution; Cyclophosphamide; Female; Humans; Ifosfamide; Leuk

1993
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administr

1993
Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Ch

1993
Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cispl

1993
Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration S

1993
Epirubicin and ifosfamide in advanced soft tissue sarcoma: a phase II study.
    Cancer investigation, 1993, Volume: 11, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubici

1993
Chemotherapy administration and data collection in an EORTC collaborative group--can we trust the results?
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Data Collection; Doxorubicin; Granulocyte-Mac

1993
High-dose ifosfamide in the treatment of advanced soft tissue sarcomas.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 7

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Female; Humans; If

1996
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors.
    Cancer, 1996, Aug-15, Volume: 78, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosp

1996
Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:7

    Topics: Acute Disease; Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chronic Disea

1996
The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma.
    Journal of chemotherapy (Florence, Italy), 1996, Volume: 8, Issue:3

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplas

1996
Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
    Anti-cancer drugs, 1996, Volume: 7, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, High Pressur

1996
[High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
    Bulletin du cancer, 1997, Volume: 84, Issue:2

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Clonazepam; Dose-Response Relations

1997
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Dose-Response Relationsh

1997
Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th

1997
Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Granulocyte Co

1997
A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas.
    Medical and pediatric oncology, 1998, Volume: 30, Issue:4

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Child, Pr

1998
Increased systemic toxicity of sarcoma chemotherapy due to combination with the P-glycoprotein inhibitor cyclosporin.
    International journal of clinical pharmacology and therapeutics, 1998, Volume: 36, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe

1998
Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS)
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Granulocyte-Macrophage Colony-Stimulating Fa

1998
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dose-Respon

1998
High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Feasib

1998
Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre

1999
Role of chemotherapy in the treatment of infantile fibrosarcoma.
    Medical and pediatric oncology, 1999, Volume: 33, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Dactinomycin; Disease

1999
Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage-colony stimulating factor in patients with soft tissue or bone sarcoma.
    Cancer, 2000, May-01, Volume: 88, Issue:9

    Topics: Adult; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chi-Square Distribu

2000
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
    British journal of clinical pharmacology, 2000, Volume: 49, Issue:6

    Topics: Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Area Under Curve; Computer Simulation; F

2000
The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma.
    Cancer, 2000, Jul-01, Volume: 89, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule

2000
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
    Anti-cancer drugs, 2000, Volume: 11, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Doxorubicin; Drug Therapy, Combination;

2000
Radiologist review versus group peer review of claimed responses in a phase II study on high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the EORTC Soft Tissue and Bone Sarcoma Group.
    Anti-cancer drugs, 2000, Volume: 11, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Middle Aged; Peer Re

2000
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Nov-01, Volume: 18, Issue:21

    Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combin

2000
Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2000, Volume: 26, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, C

2000
Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dis

2001
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:3

    Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot

2001
Ifosfamide and epirubicin combination in untreated sarcomas: two treatment schedules.
    Onkologie, 2001, Volume: 24, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship,

2001
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:9

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Pro

2001
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
    Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bronchiolit

2001
Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
    Cancer, 2002, Feb-01, Volume: 94, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined

2002
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma Group.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Europe; Humans; Ifosfamide; Sarcoma;

1992
Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Drug Administ

1992
Doxorubicin (or epidoxorubicin) combined with ifosfamide in the treatment of adult advanced soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Humans; Ifosfamide; Sarcoma

1992
Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Female; G

1991
Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship,

1990
Ifosfamide in soft tissue sarcoma.
    JPMA. The Journal of the Pakistan Medical Association, 1990, Volume: 40, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Doxorubicin; Etoposide;

1990
Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:1

    Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Female; Hematuria; Human

1989
Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:9

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bra

1989
Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Dactinom

1989
Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Infections;

1986
The treatment of soft tissue sarcomas with focus on chemotherapy: a review.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1986, Volume: 5, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy;

1986
Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:3

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Middle

1987
Ifosfamide--pharmacology, safety and therapeutic potential.
    Cancer treatment reviews, 1985, Volume: 12, Issue:1

    Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu

1985

Other Studies

138 other studies available for ifosfamide and Soft Tissue Neoplasms

ArticleYear
There is more to soft tissue sarcomas than just grade and size.
    Cancer, 2022, Jan-01, Volume: 128, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms

2022
The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2021, Volume: 165

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Retrospectiv

2021
Standardization of evaluation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas.
    BMC cancer, 2022, Jan-21, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Dr

2022
The role of perioperative chemotherapy in primary high-grade extremity soft tissue sarcoma: a risk-stratified analysis using PERSARC.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 165

    Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Humans; Ifosfamide; Retrospective Studi

2022
Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
    Japanese journal of clinical oncology, 2022, May-31, Volume: 52, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Humans; Ifosfamid

2022
Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy.
    Cancer medicine, 2022, Volume: 11, Issue:18

    Topics: Adolescent; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

2022
Prediction of the therapeutic efficacy of epirubicin combined with ifosfamide in patients with lung metastases from soft tissue sarcoma based on contrast-enhanced CT radiomics features.
    BMC medical imaging, 2022, 07-26, Volume: 22, Issue:1

    Topics: Epirubicin; Humans; Ifosfamide; Lung Neoplasms; Retrospective Studies; Sarcoma; Soft Tissue Neoplasm

2022
Clear cell sarcoma of soft tissue with plasmacytoid morphology: A rare case report.
    Medicine, 2022, Nov-04, Volume: 101, Issue:44

    Topics: Adolescent; Doxorubicin; Extremities; Humans; Ifosfamide; Male; Sarcoma, Clear Cell; Soft Tissue Neo

2022
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male;

2022
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male;

2022
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male;

2022
Rare presentation in a rare case of pancreatic extraosseous Ewing's sarcoma: A case report.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Adolescent; Cyclophosphamide; Dysuria; Epirubicin; Etoposide; Flank Pain; Humans; Ifosfamide; Male;

2022
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti

2023
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti

2023
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti

2023
Epirubicin, cisplatin plus ifosfamide versus standard chemotherapeutic regimens for advanced/unresectable primary thoracic sarcomas.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Humans; Ifosfamide; Prospecti

2023
Strategies for the Treatment of Infantile Soft Tissue Sarcomas With BCOR Alterations.
    Journal of pediatric hematology/oncology, 2023, 08-01, Volume: 45, Issue:6

    Topics: Biomarkers, Tumor; Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Infant

2023
Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023, Volume: 25, Issue:12

    Topics: Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Retrospective Studies; Sarcoma; Soft Ti

2023
Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy.
    International journal of molecular sciences, 2023, Jul-31, Volume: 24, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Ifosfamide; Sarcoma; Soft Tissu

2023
Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos

2020
Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.
    American journal of clinical oncology, 2020, Volume: 43, Issue:6

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antineoplastic Combined Chemothera

2020
A case of spindle cell dominant histiocytic sarcoma showing a complete remission after first-line chemotherapy with doxorubicin and ifosfamide.
    Journal of chemotherapy (Florence, Italy), 2020, Volume: 32, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Histiocytic Sarc

2020
[A Case of Primary Ewing Sarcoma of the Kidney Treated with Multidisciplinary Approach].
    Hinyokika kiyo. Acta urologica Japonica, 2020, Volume: 66, Issue:9

    Topics: Female; Homeobox Protein Nkx-2.2; Homeodomain Proteins; Humans; Ifosfamide; In Situ Hybridization, F

2020
Primary dedifferentiated Liposarcoma of vagina: a first case report.
    Diagnostic pathology, 2021, Jan-09, Volume: 16, Issue:1

    Topics: Adult; Antineoplastic Agents; Disease-Free Survival; Doxorubicin; Drug Therapy, Combination; Female;

2021
Apatinib with doxorubicin and ifosfamide as neoadjuvant therapy for high-risk soft tissue sarcomas: a retrospective cohort study.
    Investigational new drugs, 2021, Volume: 39, Issue:6

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant

2021
Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group.
    Japanese journal of clinical oncology, 2021, Oct-05, Volume: 51, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D

2021
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jul-10, Volume: 35, Issue:20

    Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla

2017
Establishment of a spontaneously transformed cell line (JU-PI) from a myxoinflammatory fibroblastic sarcoma.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2018, Volume: 40, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Transformed; Cell Proliferation; D

2018
The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk.
    JAMA oncology, 2018, 09-01, Volume: 4, Issue:9

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Extremities;

2018
ASO Author Reflections: Chemoradiation for High-Risk Soft Tissue Sarcomas.
    Annals of surgical oncology, 2018, Volume: 25, Issue:Suppl 3

    Topics: Chemoradiotherapy; Epirubicin; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms

2018
Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma.
    International journal of clinical oncology, 2019, Volume: 24, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant;

2019
Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2013, Volume: 189, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Combined Modal

2013
Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas.
    Clinical orthopaedics and related research, 2014, Volume: 472, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy;

2014
Extraskeletal Osteosarcoma: An International Rare Cancer Network Study.
    American journal of clinical oncology, 2016, Volume: 39, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc

2016
[End-stage renal disease after sarcoma therapy - case 3/2014].
    Deutsche medizinische Wochenschrift (1946), 2014, Volume: 139, Issue:15

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diagnosis, Differential

2014
The Impact of Perioperative Chemotherapy Timing in Conjunction With Postoperative External-Beam Radiation Therapy on Extremity Soft-Tissue Sarcomas Outcome.
    American journal of clinical oncology, 2016, Volume: 39, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad

2016
Extraskeletal myxoid chondrosarcoma of the thigh in a child: a case report.
    Journal of orthopaedic surgery (Hong Kong), 2014, Volume: 22, Issue:3

    Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Chondrosar

2014
A retrospective analysis of lung metastasis in 64 patients with alveolar soft part sarcoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015, Volume: 17, Issue:10

    Topics: Adolescent; Adult; Age Factors; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chem

2015
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
    Future oncology (London, England), 2015, Volume: 11, Issue:11 Suppl

    Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; C

2015
Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
    Clinical orthopaedics and related research, 2015, Volume: 473, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant;

2015
Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma.
    American journal of clinical oncology, 2018, Volume: 41, Issue:2

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Disease

2018
Adjuvant chemotherapy for soft tissue sarcomas: a 10-year mono-institutional experience.
    Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2016
Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
    Pediatric blood & cancer, 2016, Volume: 63, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cyclophosphamide; Doxorubicin

2016
Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience.
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2016, Volume: 20, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Doxorubici

2016
Singapore Cancer Network (SCAN) Guidelines for the Initial Evaluation, Diagnosis, and Management of Extremity Soft Tissue Sarcoma and Osteosarcoma.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Chemotherapy, Adjuvan

2015
Combination of Cisplatin, Ifosfamide, and Adriamycin as Neoadjuvant Chemotherapy for Extremity Soft Tissue Sarcoma: A Report of Twenty-Eight Patients.
    Medicine, 2016, Volume: 95, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin

2016
VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.
    Medicine, 2017, Volume: 96, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisp

2017
The risk of postoperative complications and functional impairment after multimodality treatment for limb and trunk wall soft-tissue sarcoma: Long term results from a monocentric series.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, Volume: 43, Issue:6

    Topics: Abdominal Wall; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplast

2017
A rare presentation of myxofibrosarcoma as a Pancoast tumor: a case report.
    Journal of medical case reports, 2017, Mar-07, Volume: 11, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Biopsy, Large-Core Needle; Blepharoptosis; Fibrosarcoma; Head and

2017
Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 76

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cerebellar

2017
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Apr-15, Volume: 15, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-U

2009
Her2, EGFR and TOPIIA gene amplification and protein expression in synovial sarcoma before and after combined treatment.
    Polish journal of pathology : official journal of the Polish Society of Pathologists, 2009, Volume: 60, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents; Combined Modality Therapy; DNA Topoisomerases, Type II; DN

2009
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
    Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Mod

2009
[Positron emission tomography as a tool for early prediction of therapy outcome in soft tissue sarcoma].
    Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:39

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Doxorubicin; Etoposide;

2009
Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy?
    The oncologist, 2009, Volume: 14, Issue:10

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod

2009
[A rare tumour with a distinctive histological appearance].
    Annales de pathologie, 2010, Volume: 30, Issue:2

    Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemo

2010
Mestastatic gastric cancer from malignant fibrous histiocytoma.
    Revista espanola de enfermedades digestivas, 2011, Volume: 103, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dio

2011
High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Oncology, 2011, Volume: 80, Issue:3-4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease-Free Survival; Female; Human

2011
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.
    Journal of surgical oncology, 2012, Aug-01, Volume: 106, Issue:2

    Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2012
Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Epi

2013
[Treatment and prognosis of stage IV alveolar soft part sarcoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Dacarbazine;

2012
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma.
    Anticancer research, 2013, Volume: 33, Issue:2

    Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Agents; Epirubicin; Female; Granulocyte Colony-S

2013
Salvage chemotherapy for advanced sarcoma patients: a single-institution experience survey.
    Journal of experimental & clinical cancer research : CR, 2002, Volume: 21, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; D

2002
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Cancer, 2002, Sep-15, Volume: 95, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali

2002
[Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2002, Volume: 21, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Female

2002
Embryonal rhabdomyosarcoma presenting in an adult: a case report and discussion of immunohistochemical staining.
    The American Journal of dermatopathology, 2003, Volume: 25, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Co

2003
Chemotherapy of soft tissue sarcoma--a clinical evaluation of treatment over ten years.
    Acta oncologica (Stockholm, Sweden), 2003, Volume: 42, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin

2003
Has "MAID" made it in the management of high-risk soft-tissue sarcoma?
    International journal of radiation oncology, biology, physics, 2003, Jul-15, Volume: 56, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Ex

2003
Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group.
    Oncology, 2003, Volume: 65, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp

2003
The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Anti

2004
The effect of multidrug chemotherapy on bone graft augmented prosthesis fixation.
    Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 2005, Volume: 23, Issue:4

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che

2005
Alveolar soft part sarcoma: a rare and enigmatic entity.
    Clinical orthopaedics and related research, 2005, Volume: 438

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophos

2005
[Emergent treatment of a malignant peripheral epineurial tumour].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2006, Volume: 77, Issue:7

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo

2006
Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma.
    Wiener klinische Wochenschrift, 2005, Volume: 117, Issue:23-24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubicin; Femal

2005
[Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F

2006
[Preoperative adjuvant therapy for primary malignant bone tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactinomycin; Doxo

2007
[Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe

2007
F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas.
    Clinical nuclear medicine, 2008, Volume: 33, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Female; Fluorodeoxyglucose F18

2008
[Clinical evaluation on the sensitivity test for anti-cancer agents in malignant bone and soft-tissue tumors].
    Gan no rinsho. Japan journal of cancer clinics, 1984, Volume: 30, Issue:9 Suppl

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide;

1984
High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna;

1983
High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1983, Volume: 11, Issue:2

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Human

1983
[Extraosseous Ewing's sarcoma].
    RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1995, Volume: 162, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin; Diag

1995
[Combination effect of pirarubicin, ifosfamide, and vincristine sulfate in the treatment of advanced synovial sarcoma--report of a case].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Cystitis; Doxorubicin; Female; Hemo

1995
Myxoid liposarcoma. Experience with chemotherapy.
    Cancer, 1994, Aug-15, Volume: 74, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha

1994
Selection of large and objectively measurable target lesions in EORTC phase II trials: impact on recruitment and response rate. EORTC Soft Tissue and Bone Sarcoma Group (STBSG).
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Doxorubicin; Gra

1993
[Intensive chemotherapy for alveolar soft part sarcoma with lung metastasis in a child].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Cyclophosphamide; Dactinomycin; Do

1993
Chemotherapy in the management of infantile fibrosarcoma.
    Medical and pediatric oncology, 1993, Volume: 21, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubic

1993
[Soft tissue tumors: indications and results of hyperthermia].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 1993, Volume: 64, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali

1993
Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Grou
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Disea

1993
Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31, Issue:5

    Topics: Adult; Aged; Humans; Ifosfamide; Magnetic Resonance Spectroscopy; Middle Aged; Phosphorus; Phosphory

1993
[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:4

    Topics: Administration, Intravesical; Adolescent; Adult; Aluminum Hydroxide; Bone Neoplasms; Child, Preschoo

1993
Treatment results obtained in metastatic soft-tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F

1993
Ifosfamide combination regimens for soft-tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fem

1993
Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Dru

1993
A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adults.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Administration Schedu

1993
Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone

1993
The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Doxorubicin; Fema

1993
Cytogenetics as an adjunct in establishing a definitive diagnosis of synovial sarcoma by fine-needle aspiration.
    Cancer, 1997, Jun-25, Volume: 81, Issue:3

    Topics: Adult; Biopsy, Needle; Cytogenetics; Diagnosis, Differential; DNA, Neoplasm; Humans; Ifosfamide; Kar

1997
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis.
    Cancer chemotherapy and pharmacology, 1997, Volume: 40, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Breast Neoplasms; Carcinoma, Transitional Cell; D

1997
The use of a systemic therapy checklist improves the quality of data acquisition and recording in multicentre trials. A study of the EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Data Collection; Doxorubicin; Granul

1997
[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:14

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Drug Administration Sch

1997
[Chemotherapy for pulmonary metastases of soft tissue sarcoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administra

1998
High-dose ifosfamide for soft tissue sarcomas: set the scene, or senescence?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Dose-Response Relationship, Drug; Human

1998
Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biot

1998
Treatment of soft-tissue sarcomas: high-dose ifosfamide or combination of ifosfamide and etoposide?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot

1999
RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
    Bone marrow transplantation, 1999, Volume: 24, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Purging; Bone N

1999
Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamide.
    American journal of clinical oncology, 1999, Volume: 22, Issue:5

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents,

1999
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.
    British journal of cancer, 1999, Volume: 81, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Div

1999
Impact of neoadjuvant chemotherapy on postoperative morbidity in soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-01, Volume: 18, Issue:19

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy

2000
Large, deep, high-grade extremity sarcomas: treating tumors of the flexor fossae.
    Surgical oncology, 1999, Volume: 8, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Combined Modality Therapy; Dose Fractionatio

1999
Comparison of double and triple high-dose chemotherapy with autologous blood stem cell transplantation in patients with metastatic breast cancer.
    Stem cells (Dayton, Ohio), 2001, Volume: 19, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Dose-Response

2001
Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials.
    Biometrics, 1999, Volume: 55, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Biometry; Clinical Trials as Topic; Humans; Ifosfamide; Leukemia,

1999
Immunoglobulin D myeloma presenting as an extraosseous soft tissue tumor.
    Skeletal radiology, 2001, Volume: 30, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Humans; Ifosfamide;

2001
Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jul-01, Volume: 19, Issue:13

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; C

2001
Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Aug-14, Volume: 98, Issue:17

    Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Catechols; Child; Chromosome Bre

2001
Systemic therapy for advanced soft-tissue sarcomas.
    Current oncology reports, 2002, Volume: 4, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Doxorubicin; G

2002
High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases.
    Bone marrow transplantation, 1992, Volume: 10, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chil

1992
Epirubicin/dacarbazine rapidly alternated with ifosfamide in the treatment of metastatic soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Epirubicin; Fe

1992
A new approach to the study of ifosfamide metabolism by the analysis of human body fluids with 31P nuclear magnetic resonance spectroscopy.
    The Journal of pharmacology and experimental therapeutics, 1992, Volume: 260, Issue:3

    Topics: Body Fluids; Humans; Ifosfamide; Magnetic Resonance Spectroscopy; Sarcoma; Soft Tissue Neoplasms

1992
Epirubicin plus ifosfamide and dacarbazine (EID) in advanced soft tissue sarcomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3 Suppl 2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Epirubicin; Follow-U

1992
Ifosfamide vs cyclophosphamide in cancer therapy.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:5

    Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Female; Genital Neoplasms,

1991
Chemotherapy in perineal leiomyosarcoma.
    Gynecologic oncology, 1992, Volume: 44, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Female; H

1992
Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co

1990
Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1990, Volume: 1, Issue:5

    Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Drug

1990
Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
    Onkologie, 1990, Volume: 13, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dos

1990
Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio

1990
Primary chemosensitivity and secondary drug resistance of xenografted soft part sarcomas.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1989, Volume: 165, Issue:7

    Topics: Animals; Bleomycin; Doxorubicin; Drug Resistance; Female; Histiocytoma, Benign Fibrous; Humans; Ifos

1989
Mesna: continuous or bolus infusion?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:6

    Topics: Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; M

1989
Characterization and chemotherapy of human soft tissue sarcoma (STS) lines grown in nude mice.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1989, Volume: 165, Issue:7

    Topics: Animals; Cyclophosphamide; Doxorubicin; Female; Fibrosarcoma; Histiocytoma, Benign Fibrous; Humans;

1989
[A case from practice (134). Patient: Mr. J.D., 1956, electrician].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1989, Mar-21, Volume: 78, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Doxorubicin; Heart Neoplasms

1989
Combination chemotherapy with doxorubicin, dacarbazine, and ifosfamide in advanced adult soft tissue sarcoma. Canadian Sarcoma Group--National Cancer Institute of Canada Clinical Trials Group.
    Journal of the National Cancer Institute, 1989, Oct-04, Volume: 81, Issue:19

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F

1989
Prediction of ifosfamide/mesna associated encephalopathy.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Electroencephalography; Female; Huma

1986
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre

1986
Treatment of advanced soft tissue and osteogenic sarcomas with continuous infusion of ifosfamide and mesna.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Mercaptoethanol; Mesna; Middle Aged; Osteo

1986
A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma.
    Cancer chemotherapy and pharmacology, 1988, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Doxorubicin; Drug Ev

1988
A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio

1988
[Results of whole lung irradiation and chemotherapy in comparison with partial lung irradiation in metastasizing, undifferentiated soft tissue sarcomas].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1988, Volume: 164, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F

1988
Ifosfamide: an old drug recently rediscovered.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:6

    Topics: Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Neoplasms; Sarcoma; Soft Tissue

1988
Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults. A preliminary analysis.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluatio

1986
Alternatives to CYVADIC combination therapy of soft tissue sarcomas.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin

1986
The role of ifosfamide in paediatric soft tissue sarcomas.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dactinomycin; Drug Evaluation; Humans; Ifosfa

1986
A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Cyclophosphamide; Drug Evaluation; Femal

1986
Alternatives to CYVADIC-combination therapy of soft tissue sarcomas.
    Klinische Wochenschrift, 1985, Nov-15, Volume: 63, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dacarbazin

1985
Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma.
    Cancer treatment reports, 1985, Volume: 69, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cystitis; Drug

1985